FIELD OF INVENTION

This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines and polyamine derived tyrosine phosphatase inhibitors/PPARα and PPARγ partial agonists/partial antagonists for the treatment of neurological, cardiovascular, endocrine and other disorders in mammalian subjects, and more specifically to the therapy of Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease, Binswanger's disease, Olivopontine Cerebellar Degeneration, Lewy Body disease, Diabetes, Stroke, Atherosclerosis, Myocardial Ischemia, Cardiomyopathy, Nephropathy, Ischemia, Glaucoma, Presbycussis, Cancer, Osteoporosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis and as Antidotes to Toxin Exposure.

CHEMICAL AND THERAPEUTIC BACKGROUND

Chemistry

There are seven groups of polyamines described herein, (1) predominately linear tetraamines and polyamines linked by 1,3-propylene and/or ethylene groups, those derived from 1,3-bis-[(2′-aminoethyl)amino]propane (2,3,2-tetramine); (2) predominately branched tetraamines and polyamines linked by 1,3-propylene and/or ethylene groups; (3) cyclic polyamines linked by 1,3-propylene and/or ethylene groups, ), those derived from the macrocycle 1,4,8,11-tetraazacyclotetradecane (cyclam); (4) combinations of linear, branched and cyclic polyamines linked by one or more 1,3-propylene and/or ethylene groups, (5) substituted polyamines, (6) polyamines derivatized to form tyrosine phosphatase inhibitor molecules with linear or branched chains attached and (7) derivatives of 2,2′-diaminobiphenyl with linear or branched chains attached. Of the collection of compounds described, most are not presently known but a few have been prepared previously.

Inherited and Acquired Mitochondrial DNA Damage

Individuals carrying mild mitochondrial DNA base substitutions manifest late onset diseases like Parkinson's and Alzheimer's diseases and familial deafness, whereas persons with moderately deleterious base substitutions develop Type II diabetes, Leber's Hereditary Optic Neuropathy, Myclonic Epilepsy and Ragged Red Fiber Disease (MERRF). Individuals with severely deleterious base substitutions develop pediatric onset myopathies, dystonias and Leigh's syndrome. Wallace D. C. (1992 a,b) suggests that aging and common degenerative diseases result from energetic decline caused by inherited oxidative phosphorylation (OXPHOS) gene defects and acquired somatic mutations. Mild mitochondrial deoxyribonucleic acid (DNA) rearrangements and duplications cause maternally inherited adult-onset diabetes and deafness. More severe rearrangements and deletions have been associated with adult-onset Chronic Progressive External Ophthalmoplegia (CPEO) and Kearns-Sayre Syndrome (KSS) and Pearson's Marrow/Pancreas Syndrome. Primary oxidative phosphorylation (OPHOS) diseases frequently have a delayed onset organ selectivity and an episodic, progressive course. For example the A3243G mutation associated with mitochondrial encephalopathy, lactic acidemia, stroke-like episodes (MELAS) can pure a pure cardiomyopathy, pure diabetes and deafness, or pure external ophthalmoplegia (Naviaux R. K. 2000).

The level of oxidative damage to mitochondrial and nuclear DNA, as measured by 8-hydroxy-2′-deoxy guanosine increases with age (Mecocci P. et al 1993) and oxidative damage to mitochondrial DNA occurs in Alzheimer's disease (Mecocci P. et al 1994 and 1998).

Some organs may be more prone to oxidative damage due to lack of protective substances, for example uric acid an antioxidant and transition metal chelator (Ames B. N. et al 1981) is not present in brain that may limit recovery from ischemic reperfusion damage and metal accumulation post stroke.

Examples of Diseases Where Mitochondrial DNA Malfunctions

In Parkinson's disease reduced glutathione is depleted due to loss of endogenous polyamines, thus reducing the activity of glutathione peroxidase and permitting oxidative damage. Oxidative damage disintegrates mitochondrial DNA into hundreds of types of mitochondrial DNA fragments which causes release of apoptotic factors and cell death (Ozawa T. et al 1997).

Mitochondrial DNA deletions in brain tissue also increase with age and the increase varies from one brain region to another (Corral-Debrinski M. et al 1992), deletions being highest in the substantia nigra and striatum (Soong N. W. et al 1992) and is also regionally distributed in Alzheimer's disease (Corral-Debrinski M. et al 1994). Environmental agents and nuclear gene defects may cause mitochondrial diseases by predisposing to multiple mitochondrial DNA deletions or quantitative depletions of mitochondrial DNA content A reversible depletion of mitochondrial DNA occurs during zidovudine (AZT) therapy (Arnaudo E. et al 1991). Adriamycin inhibits mitochondrial cytochrome c oxidase (COX if) gene transcription leading to cardiomyopathy (Papadopoulou L. C. et al 1999). Mendelian traits causing qualitative and quantitative changes in mitochondrial DNA have been observed (Zeviani M et al 1995). Nuclear recessive factors can also affect mitochondrial translation and cause age-related respiration deficiency (Isobe K. et al 1998). Wolfram syndrome can be caused by either a mitochondrial or nuclear gene defect (Bu X. et al 1993).

Mitochondrial disorders with neurologic manifestations include; Ptosis, ophthalmoplegia, exercise intolerance, fatigability, myopathy, ataxia, seizures, myoclonus, stroke, optic neuropathy, sensorineural hearing loss, dementias, peripheral neuropathy, headache, dystonia, myelopathy. Mitochondrial disorders with systemic manifestations include; cardiomyopathy, cardiac conduction defects, short stature, cataract, pigmentary retinopathy, metabolic acidosis, nausea and vomiting, hepatopathy, nephropathy, intestinal pseudo-obstruction, pancytopenia, sideroblastic anemia, diabetes mellitus, exocrine pancreatic dysfunction and hypoparathyroidism.

DNA Damage in Neurodegenerative Disorders

Mitochondrial DNA is not protected by histones and lacks a pyrimidine dimer repair system (Clayton DA et al 1974). Mitochondrial DNA has a relatively short half life of six to ten days compared with an up to one month half life of nuclear DNA. The error insertion frequency of polymerase γ is approximately 1 in 7,000 bases, leading to 2-3 mismatched nucleotides per cycle of replication. Hypoxia induces damage to nuclear DNA and to a greater extent to mitochondrial DNA (Englander E. et al 1999). Nuclear and mitochondrial DNA repair declines during aging in neurons and in cortical glial cells (Schmitz C. et al 1999). 8-hydroxyguanosine (8-OHG) immunoreactivity is increased in the substantia nigra, nucleus raphe dorsalis and occulomotor nucleus of Parkinson's disease patients, and 8-HG immunoreactivity is also increased in the substantia nigra of Olivopontine cerebellar degeneration (OCD or MSA) and Lewy body disease patients. Lewy bodies were proposed to be degenerating mitochondria (Gai W. P. et a] 1977). Mitochondria partially though not completely repair DNA damage caused by bleomycin (Shen C. 1995). Polyamines promote repair of X-ray induced DNA strand breaks (Snyder R. D. 1989). Polyamine depletion caused by α-difluoromethylornithine (DFMO) increases the number of strand breaks caused by 1,3-bis(2chloro-ethyl)-1-nitrourea (BCNU) (Cavanaugh P. F. et al 1984). Physiological concentrations of spermine and spermidine prevent single strand DNA breaks induced by superoxide (102) (Khan A. U. et al 1992). L-DOPA and Cu(II) generate reactive oxygen species, conversion of guanine to 8-hydroxyguanine and cause strand breakage of DNA (Husain S. et al 1995). The metal catalyzed oxidation of dopamine and related amines to quinones and semiquinones occurs during pigment deposition and may precipitate cellular damage in Parkinson's and Lou Gehrig's diseases (Levay G. et al 1997). Melanin in association with Cu(II) is also capable of causing DNA strand breakage (Husain S. et al 1997). Copper concentrations in the cerebrospinal fluid of Alzheimer's patients is increased 2.2 fold and caeruloplasmin concentrations is also increased (Bush ALL et al 1994). Copper concentrations are elevated to 0.4 mM and iron and zinc to 1 mM in the neuropil of Alzheimer's brain (Lovell M. et al 1998, Smith M. A. et al 1997).

Mitochondrial DNA content is depleted in Parkinsonian brain and following MPTP administration in experimental animals due to deficient DNA replication in both instances (Miyako K. et al 1997 and 1999). MPP+destabilizes D-loop structure thereby inhibiting the transition from transcription to replication of mitochondrial DNA (Umeda S. et al 2000).

Alzheimer's disease patients brains have decreased levels of mitochondrial DNA, increased levels of 8-OHdeoxyguanosine and increased DNA fragmentation (de la Monte S. M. et al 2000). Increased levels of point mutations, for example at nucleotide pair 4366 in the tRNA^GLN gene was observed (Shoffner J. M. et al 1993). The risk of Alzheimer's disease increases when a maternal relative is afflicted with the disease (Duara R. et al 1993, Edland S. D. et al 1996).

DNA damage was proposed as a cause of Lou Gehrig's disease by Bradley W. G et al and deficiency of cytochrome c oxidase activity and a cytochrome c microdeletion were observed by Borthwick G. M. et al (1999) and Comi G. P. et al (1998).

A decreased activity of mitochondrial complex IV and citrate synthase was observed in Olivopontine Cerebellar Degeneration (OCD or MSA) (Schapira A. H. V. 1994, 1998).

Biological Actions of Polyamines that Maintain Brain Function and Prevent Neurodegeneration

However the pathology of several disease states which are described below involves more than the initial DNA damage and correspondingly the influence of therapeutic agents in these diseases involves control of DNA damage and other cellular injuries simultaneously.

I previously reported the ability of 2,3,2 tetramine in Murphy U.S. Pat. No. 5,906,996 to prevent MPTP induced dopamine loss and the applicability of such compounds in the treatment of neurodegeneration, this being notated herein in its entirety by this reference.

A model of neurodegeneration involving Parkinson's, Alzheimer's, Olivopontine Cerebellar Degeneration, Lewy Body, Binswanger's and Lou Gehrig's diseases involving a similar constellation and cascade of events, whereby the final disease is determined by the duration of damage and the anatomical distribution of damage was described. The principal highlights of this pattern of neurodegeneration and its treatment by polyamines are summarized as follows:

The Neurodegenerative Pathway in Parkinson's, Olivopontine Cerebellar Atrophy (MSA), Alzheimer's, Lewy Body, Binswanger's and Lou Gehrig's Diseases

There are five principal aspects of neuronal damage in this pattern of neurodegeneration all of which are prevented by optimized polyamine molecules; Mitochondrial DNA Damage, Growth Factor Functions, Receptor Activities, Energetics and Redox Homeostasis and Deposition of Amyloid.

Cascade of Events in the Pathogenesis of Neurodegeneration:

Mitochondrial DNA is damaged by dopamine and xenobiotics in the presence of reduced levels of naturally occurring polyamines.

Polyamines competitively block the uptake of xenobiotics which depigment pigment Depigmentation releases organic molecules and free metals which damage mitochondrial DNA bases. Polyamines protect DNA from damage by organic molecules by steric interactions (Baeza L. et al 1992). They sequester the metals directly and induce transcription of metallothionein (Goering P. L. et al 1985), the metals being catalytic in reactions damaging DNA bases. They also induce transcription of growth factors such as nerve growth factor, brain derived neuronotrophic factor (Chu P. et al 1995, Gilad G. et al 1989. Polyamines regulate the activity N-methyl-d-aspartate (NMDA) receptor and affect the level of agonism or antagonism at the MK801 ion channel (Beneviste M. Et al 1993, McGurk J. F. 1990) and the activity of protein kinase C (Mezzetti G et al 1988, Moruzzi M. S. et al 1990, 1995).

Polyamines regulate redox homeostasis by binding glutathione (Dubin D. T. 1959). These primary deficits associated with polyamine deficiency cause the neuronal dedifferentiation processes of these diseases via the changes in growth factor levels or ratios, the rapid entry of calcium via the MK801 ion channel and the metabolic consequences by damaged RNA transcripts causing production of defective cytochromes.

Secondarily defective cytochromes are proteolysed and release enkephalin by products and also release free iron into the mitochondrial matrix The iron is leached from damaged calcium laden mitochondria into the cytosol of the neurons. NMDA receptor activation causes excess calcium entry into cells.

Thirdly gross elevation of the free level of a metal such as iron causes displacement of other metals such as copper, nickel, cobalt and lead from sites where they are bound. One or more of these metals overactivate preasapatate proteases (Abraham 199a, 199b, 1992, Black 1989, Blomgren 1989, Chakrabarti 1989, Dawson 1987, Dawson 1988, Edelstein 1988, Hamakubo 1986, Koistra 1984, Matus 1987, Perlmutter L. S. et al 1988, Press E. M. 1960, Rabbazoni B. L. 1992, Rose C. 1988, Rose C. 1989, Scanu A. M. 1987, Whitaker J. N. 1979) which can produce β-amyloid and tangle associated proteins. In Parkinson's Disease and Alzheimer's Disease there is an increase in free copper levels in the absence of an absolute increase in copper levels or more likely an actual decrease in total tissue copper levels due to its loss in the cerebrospinal fluid. The free copper will activate amine oxidase, tyrosinase, copper zinc superoxide dismutase and monoamine oxidase B. The preaspartate proteases may be activated by several divalent metal ions including such as zinc, iron, calcium, cobalt. The literature on these proteases indicates that zinc and calcium and copper are particularly likely. Given a role for divalent metals in activating preaspartate proteases and amyloid production as a tertiary event in this model, it is in concordance with the clinical situation whereby patients present with Parkinson's Disease and subsequently Alzheimer's Disease rather than the converse. In Guamanian Parkinsonian Dementia the plaque formation likewise follows motor neuron and Parkinsonian pathology after many years or decades.

More specifically, therapeutic polyamine compounds like 2,3,2-tetramine have multiple actions on this cascade of events extending from DNA damage to amyloid production;

a) Competitive inhibition of uptake of xenobiotics at the polyamine transport site, such organic molecules being a cause of depigmentation and DNA damage; b) Steric shielding of DNA from organic molecules by compacting DNA, c) Limitation of mitochondrial DNA damage by removal of free copper, iron, nickel, mercury and lead ions by the presence of a polyamine, d) Induction of metallothionein gene transcription; e) Induction of nerve growth factor, brain derived neuronotrophic factor and neuronotrophin-3 gene transcription; f) Regulation of affinity of NMDA receptors and blockade of the MK801 ion channel; g) Inhibition of protein kinase C; h) Mitochondrial reuptake of calcium; i) Binding and conservation of reduced glutathione; j) Induction of ornithine decarboxylase by glutathione; k) Maintenance of the homeostasis of the redox environment in brain; 1) Non toxic chelation of divalent metals in brain, m) Regulation of activity of preaspartate proteases; n) Inhibition of acetylcholinesterase and butyrylcholinesterase; o) Blockade of muscarinic M₂ receptors; p) Maintenance of ratio of membrane phosphatidylcholine: phosphatidylserine ratio, q) Inhibition of superoxide dismutase, amine oxidase, monoamine oxidase B by binding of free copper, r) Regulation of brain polyamine levels in dementias with maintenance of endogenous polyamine levels; s) Blockade of neuronal n and p type calcium channels.

Success therapy must prevent glutathione loss, prevent mitochondrial DNA damage or cytochrome enzyme malfunction, prevent release of metals including calcium from mitochondria, NMDA receptor blockade, prevent hyperpigmentation and ensuing depigmentation, prevent oxidative enzyme and amyloid producing enzyme activation. Polyamines compounds described herein uniquely have the relevant profile of the above actions and prevent MPTP induced dopamine loss in an animal model.

Because none of the changes in Parkinson's or Alzheimer's diseases are pathognomic and because of the overlapping sets of mitochondrial and cytosolic events in Parkinson's disease, Guamnanian Parkinsonian dementia, Alzheimer's disease, Binswanger's diseases, Lewy body disease, hereditary cerebral hemorrhage—Dutch type, Olivopontine cerebellar atrophy and Batten's Disease it is anticipated that these compounds will be beneficial in controlling dementia development The major pathological difference between Parkinson's and Alzheimer's pathological features being the presence of amyloid in Alzheimer's disease and the diseases being closely interlinked by the evolution of Parkinson's disease into Alzheimer's disease with amyloid deposition as the former progresses. At post mortem forty percent of Parkinson brains have amyloid deposits.

The Neurodegeneration Process—Prevention & Treatment by Polyamines:

The following summarizes the principal concurrent and sequential components of neurodegeneration in Parkinson's, Alzheimer's and Lou Gehrig's diseases, the sites of cellular damage and the pivotal relationship between neurotoxins and polyamines in precipitating and preventing neurodegeneration.

Excessive exposure to xenobiotic molecules that migrate into the cell across the polyamine transport pump initiate depolymerization of pigment During depigmentation more organic molecules and stored heavy metals are released intracellularly. The excessive exogenous (xenobiotics) and endogenous quinones and semiquinones (neurotransmitter by products) organics mutate mitochondrial DNA bases randomly when catalyzed by heavy metals.

When mitochondrial DNA is damaged, the cytochrome proteins produced are dysfunctional. Breakdown of these proteins releases iron intramitochondrially and subsequently intracellularly. The inactive cytochromes fail to produce the energy storage compound adenosine triphosphate (ATP) which operates the cell's various metabolic processes.

The metals released from the pigment and the iron from the mitochondria activates various enzymes including amine oxidase that breaks down polyamines and preaspartate proteases that produce amyloid from its precursor protein. Decreasing polyamine levels below a threshold level by excessive amine oxidase activity results in a positive feedback cycle of further polyamine loss because polyamines bind and conserve the peptide glutathione (GSH) that stimulates the rate limiting enzyme of polyamine production, ornithine decarboxylase.

As well as regulating the inflow and outflow of xenobiotics and binding of toxic free metals, polyamines also compact mitochondrial DNA that is not coiled or supercoiled like nuclear DNA; they promote transcription of several neuronal growth factors; they regulate the activities of several cell surface receptor systems including the n-methyl-d-aspartate (NMDA) receptor. All of these components of neurodegeneration can be controlled using an optimized polyamine.

Peripheral Neuropathy

Peripheral neuropathy occurs in association with mitochondrial encephalomyopathies (Chu C. et al 1997). Vacuolar degeneration of dorsal root ganglia cells may consist of degenerating mitochondria Mitochondrial DNA mutations may be caused by lipid peroxidation α-lipoic acid affected improvement in streptozotocin diabetic neuropathy (Low P. A. et al 1997). Glutathione treats experimental diabetic neuropathy (Brabenboer B. et al 1995).

Probucol and Vitamin E improve nerve blood flow and electrophysiology (Cameron N. E. et al 1994, Karasu C. et al 1995). Hydroxytoluene and carvidilol were also effective in preventing damage in diabetic neuropathy (Cameron N. E. et al 1993 and Cotter M. A. et al 1995).

Optic Neuropathy

Optic neuropathy occurs in multiple sclerosis patients and occasionally these multiple sclerosis patients have LHON associated mitochondrial DNA mutations.

Optic neuropathy also occurs from toxic exposure to tobacco and methanol as in Cuban epidemic optic neuropathy (CEON) (Sadun A. and Johns D. R. et al 1994). Methanol leads to formate production that inhibits cytochrome oxidase and adenosine triphosphate production is diminished. Decrease in ATP results in decreased mitochondrial transportation and shutdown of axonal transportation.

Glaucoma

In glaucoma the M ganglion cells of the retina degenerate and there is defective axoplasmic flow (Quigley H. A. 1995). Glutamate is elevated in the vitreous body of glaucoma patients (Dreyer E. B. et al 1996), glutamate being more toxic to M ganglion cells (Dreyer M. et al 1994).

The excitotoxic cascade caused by NMDA receptor activation in the optic nerve results in excess calcium influx, increased nitric oxide synthesis and production of oxygen free radicals (Sucher N. J. et al 1997).

Diabetes Mellitus

Mitochondrial DNA Damage in Diabetes

Mitochondrial DNA content in peripheral blood was observed to be 35% lower in Non Insulin Dependent diabetics (NIDDM) than in controls Lee H. K. et al 1998) and the decline precedes the onset of diabetes. Reduced oxidative disposal of glucose results in insulin resistance in skeletal muscle and/or defective insulin secretion in pancreatic islets. Decreased mitochondrial DNA content impairs fat oxidation in the presence of increased fatty acid availability, fatty acyl CoA accumulates in the cytosol and thus causes insulin resistance (Park K. S. et al 1999).

Streptozotocin causes oxidant mediated repression of mitochondrial transcription (Kristal B. S. et al 1997) and the quantity of mitochondrial DNA decreases in the islets of diabetes prone GK rats (Serraas P. et al 1995). Forty two different mitochondrial DNA point mutations, deletions and substitutions have been associated with NIDDM (Matthews C. E. et al 1998). Mitochondrial DNA mutations such as the M3243 base substitution can also cause maturity onset diabetes of the young (MODY) and auto antibody positive insulin dependent diabetes mellitus (IDDM) (Oka Y. 1993 and 1994). Free radicals can cause deletions of the mitochondrial genome (Wei Y. H. et al 1996). Nitric oxide and hydroxyl radical production in response to environmental agents were proposed as a means of producing mitochondrial DNA damage, expression of mutated proteins which cause MHC restricted immune responses and P cell death in Type 1 diabetes by Gerbitz K. D. (1992). Reductions in β cell numbers and islet amyloidosis containing islet amyloid polypeptide occurs in a high percentage of NIDDM patients (Clark A. et al 1995).

These defects impair oxidative phosphorylation, such impairment diminishing insulin secretion. Treatment with coenzyme Q10 has been reported to be successful in a patient with the M3243 A to G mutation (Suzuki Y. et al 1995). Glucagon secretion is also decreased in diabetes mellitus associated with mitochondrial DNA defects (Odawara M. et al 1996).

Insulin dependent diabetes, autoantibody positive also occurs in patients carrying the M3243 mutation. (Oka Y. et al 1993). 8-hydroxydeoxyguanosine (80HDG) content and extent of deletion of mitochondrial DNA base 4977 deletion correlates with duration of NIDDM and the frequency of diabetic proliferative and simple retinopathy and nephropathy (Suzuki Y. et al 1999). Hyperglycemia causes oxidative damage to the mitochondrial DNA of vascular smooth muscle and endothelial cells precipitating vasculopathy (Fukagawa N. K et al 1999). High insulin levels are also implicated in damaging smooth muscle and endothelial cells (O'Brien S. F. et al 1997). Monosaturated palmitic acid causes DNA fragmentation of rat islet cells in culture. It also reduces the β cell proliferation caused by hyperglycemia. Palmitic acid also induced release of cytochrome c and apoptois of β cells (Maedler K et al 2001).

Exocytosis of Insulin

The methyl ester of succinnic acid may bypass defects in glucose transport, phosphorylation and further catabolism and stimulate insulin secretion and release (McDonald J. et al 1988 and Malaisse W. J. et al 1994). Succinate esters increase the supply of succinnic acid and acetyl CoA to the Krebs cycle (Malaisse W. J. 1993a), they stimulate insulin synthesis and release Malaise W. J. et al 1993b), they increase insulin output at high concentrations of glucose (Akkan A-G. et al 1993), they maintain insulin secretion when β cells are challenged with streptozotocin (Malaisse W. J. 1994), they enhance the inslinotropic effect of hypoglycemic sulfonylureas (Vicent D. et al 1994), they improve the secretory potential of exocrine pancreas when administered prior to streptozotocin (Akkan A. G. et al 1993), they protect against the cytotoxic effect of interleukin-1 (Eizirik D. L. et al 1994) and they do not show any glucagonotropic effect (Vicent D. etal 1994).

Glutamate also stimulates exocytosis of insulin, primarily by an intracellular mechanism acting downstream of mitochondrial metabolism, as oligomycin that abolishes the insulin release response to succinate does not inhibit the insulin release caused by glutamate (Maechler P. et al 2000). Also glutamate induced insulin release seems to require other factors such as ATP induced closure of potassium channels followed by influx of calcium and exocytosis.

Protein Kinase C and Insulin Resistance

Hyperglycemia increases the activity of protein kinase C (Lee T. S. et al 1989). Activation of protein kinase C increases the tram endothelial permeability of proteins such as albumin (Lynch J. J. et al 1990). Albumin, hyperglycemia, H₂O₂ can cause the 4977 bp mitochondrial DNA deletion associated with diabetes (Egawhary, D. N. et al 1995 and Swoboda, B. E. et al 1995). Circulating endothelial cells containing this deletion are particularly common in patients with nephropathy and peripheral vascular disease. The same deletion is also present during aging and more frequently in patients with impaired glucose tolerance or insulin resistance, hyperglycemia and free radicals being precipitants thereof (Liang P. et al 1997).

Triglyceride hydrolysis generates diacylglycerol which activates protein kinase C which promotes serine/threonin phosphorylation thus reducing tyrosine kiinase activity. Feeding animlas high fat diets increases the ratio of membrane bound to cytosolic protein kinase C sixfold. Protein kinase C α, β, ε and δ is increased in muscle of rats fed a fat rich diet (Schmitz-Pfeiffer C. et al 1997) and in regularly fed Goto-Kakizaki rats, a strain of rats with insulin resistance (Avignon A et al 1996). Inhibition of protein kinase C in rat adipocytes prevented insulin resistance (Muller H. K. et al 1991). Protein kinase C 8 is overexpressed in Psammomys preceding the onset of overt insulin resistance and is a prediabetic stage (Ikeda Y et al 1999). Protein kinase C causes retinopathy, neuropathy and nephropathy in diabetes (Koya D et al 1998).

Polyamines and Insulin Concentration

Erythrocyte spermidine levels are elevated in insulin dependent diabetic patients and patients with microalbuinuria and macroalbuminuria and retinopathy (Seghieri G. et al 1992). Spermine oxidase activity is lower in insulin dependent diabetics though not in patients with proliferative retinopathy (Seghieri G. et al 1990). Polyamines are present in high concentrations in B cells and are concentrated in secretory granules (Houggard D. M. et al 1986). Putresine, spermidine and spermine increase synthesis of (pro)insulin, however spermine increases insulin mRNA levels and promotes insulin release (Welsh N et al 1988). Spermine protects the insulin mRNA from degradation (Welsh N. 1990).

Daibetogenic Toxins

Taurine (Trachtman R et al 1995) and vitamin C (Craven P. A. et al 1997) reduced glomerular hypertrophy, albuminuria, glomerular collagen and TGF-01 accumulation in a streptozotocin induced diabetic rat model.

In streptozotocin induced diabetes metal distribution is altered, there are increases in the quantities of hepatic copper, zinc, manganese, renal copper and zinc and plasma zinc. Insulin administration returns the metal levels to within normal ranges (Failla M. I. et al 1981). In contrast to the elevated hepatic and renal zinc concentrations in diabetic pregnant rats, their fetuses have lower concentrations of hepatic zinc Uriu-Hare J. et al 1988). Higher groundwater zinc concentrations reduces the incidence of insulin dependent diabetes mellitus in childhood (Haglund B. et al 1996). Low serum zinc and hyperzincuria have been reported in the initial stages of Type 1 diabetes (Hagglof B. et al 1983). Hyperzincuria and borderline zinc deficiency also occurs in type II diabetes (Kinlaw W. B. et al 1983). Preloading animals with zinc, which induces metallothionein synthesis, metallothionein being a radical scavenger, partially prevents streptozotocin induced diabetes (Yang Y. et al 1994). Elevated metallothionein increased resistance to DNA damage and to depletion of NAD+, increased resistance to hyperglycemia and reduced β cell degranulation and necrosis (Chen H. et al 2001). Metallothionein is highly inducible and does not seem to have deleterious effects at higher concentrations.

In alloxan induced diabetes diethylenetriamine pentaacetic acid inhibits the hyperglycemic response (Grankvist K. et al 1983). Part of the cytoprotective effect of spirohydantoin-derivative aldose reductase inhibitors in diabetes may relate to their ability to chelate copper ions and thus inhibit ascorbic acid oxidation (Jiang Z. Y. et al 1991).

Iron-catalyzed peroxidative reactions may account for the diabetes found as a common side effect of transfusion siderosis, dietary iron overload and idiopathic hemochromatosis McLaren G. D. et al 1983). Plasma copper levels are higher in diabetic patients and are highest in diabetics with angiopathy and diabetics who have alterations in lipid metabolism (Mateo M. C. M. et al 1978, Noto R. et al 1983). Carboxymethyl lysine (CML) levels are twice as high in the skin collagen of diabetics as compared with age matched controls (Dyer G. D. et al), and correlate positively with the presence of retinopathy and nephropathy (McCance D. R. et al 1993).

Matrix metalloproteinase-9 (MMP-9) concentrations are increased in noninsulin dependent diabetes mellitus (NIDDM) prior to development of microalbuminuria (Ebihara L et al 1998). This proteinase is activated by zinc, calcium and oxidative stress.

Treatment with antioxidants polyethylene glycol-superoxide dismutase and N-acetyl-L-cysteine reduces MMP-9 activity (Uemura S. et al 2001). Increased MMP-9 activity is also observed in myocardial infarction, unstable angina and in atherosclerosis.

Polyamines as blockers of uptake of xenobiotics, as molecules which compact DNA and as chelates of redox metals which, redistribute metals to storage sites and induce metallothionein can prevent the damage caused by organic toxins and metal induced redox damage.

Vanadium and Insulin Sensitivity

Vanadium decrease blood glucose and D-3-hydroxybutyrate levels in diabetes, it also restores fluid intake and body weight of diabetic animals. These metabolic effects occur because vanadium decreases P-enolpyruvate carboxykinase (PEPCK) transcription, thus decreasing gluconeogenesis; secondly it decreases tyrosine aminotransferase gene expression, Thirdly it increases expression of glucokinase gene; fourthly it induces pyruvate kinase; fifthly it decreases mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase (HMGCoAS) gene expression, sixth it decreases the expression of the liver and pancreas glucose-transporter GLUT-2 gene in diabetic animals to the level seen in controls (Valera A et al 2001); seventh it increases the amount of the insulin-sensitive glucose transporter, GLUT4 by stimulating its transcription (Strout H. V. et al); eighth the metabolic effects of vanadium are mediated by inhibition of protein tyrosine phosphatases (PT). Peroxovanadium compounds irreversibly oxidize the thiol group of the essential cysteine at the PTP catalytic site (Fantus I. G. et al 1998). Vanadium is a structural analog of phosphate. Vanadium does not exhibit the growth effects and mitogenic effects of insulin and thus might avoid the macrovascular diseases consequences of hyperinsulinemia and be clinically useful in disease where insulin resistance is caused by defects in the insulin signaling pathway. Vanadium mimics the effects of insulin in restoring G proteins and adenyl cyclase activity increasing cyclic AMP levels. (Anand-Srivastava M. B. et al 1995); ninth vanadyl ion suppresses nitric oxide production by macrophages (Tsuji A. et al 1996); tenth it has a positive cardiac inotropic effect (Heyliger C. E. et al 1985); eleventh vanadium restores albumin mRNA levels in diabetic animals by increasing hepatic nuclear factor 1 (HNF 1) (Barrera Hernandez G. et al 1998); twelfth it restores triiodothyronine T₃ levels (Moustaid N. et al 1991).

In type I diabetes vanadium appears to reverse defects secondary to chronic insulin deficiency and hyperglycemia and may be useful in newly diagnosed diabetics who still have pancreatic reserve (Cam M. C. et al 2000). Vanadium is also P cell protective in streptozotocin diabetic rats (Cam M. C. et al 1999). In type II diabetes vanadium improves glucose tolerance whilst decreasing plasma insulin levels.

Improvement occurs in fasting plasma glucose, glycosylated hemoglobin levels, insulin stimulated glucose uptake and reduction of hepatic glucose output (Cohen N. et al 1995). Free fatty acid and triglyceride levels are controlled more quickly in diabetic animals than glucose levels (Cam M. C. et al 1993). Type I and Type II diabetic patients treated with vanadium had significantly less need for insulin (Goldfine A. B. et al 1995 & 2000).

The toxicity of vanadate was reduced by administering it in chelate form, sodium 4,5 dihydroxybenzene-1,3 disulfonate (Tiron) (Domingo J. L. et al 1995). The organic forms of vanadium corrected the hyperglycemia and impaired hepatic glycolysis more safely and potently than vanadium sulphate (Reul B. A. et al 1999).

Vanadium completed with the biguanide drug metformin was not more effective in lowering blood glucose in streptozotocin treated rats than bis(maltolato)oxovanadium(IV) salts (Lenny C. Y. et al 1999). Vanadate acts as a phosphate analog and binds to phosphoryl transfer enzymes, where it can assume a trigonal bipyramidal structure. Hydrogen peroxide may complex with vandium, forming pervanadate, which may oxidize the catalytic cysteine of tyrosine phsophatase (Huyer G. et al 1997).

Tyrosine Phosphatase Inhibition and Isulin Sensitivity

Tyrosine phosphatases and tyrosine kinases play crucial roles in cellular growth and differentiation, signal transduction, metabolism, motility, cytoskeletal organization, cell cell interaction, gene transcription and the immune response (Zhang Z. 1998, Li L. 2000, den Hertog J. 1999). It is estimated that there may be five hundred such tyrosine phosphatase proteins coded for in the human genome. The catalytic domains of several hundred has been sequenced and consist of an approximate two hundred and forty amino acids in the amino terminal (Walchli S. et al 2000) which contain the active site sequence (I/V)HCXXGXXR(S/T), referred to as a C(X)₅R motif (Dixon J. E 1995). The carboxyterminal is a regulatory domain.

Of the protein tyrosine phosphatases sequenced there are two groups a) transmembrane proteins of 680-2000 amino acids with extracellular domains which are likely to function as receptors for extracellular signals and b) proteins of 360-930 amino acids which appear to be entirely cytoplasmic (Krueger N. et al 1990). Protein tyrosine phosphatase 1B (PT-1B) which regulates insulin sensitivity is associated with microsomal membranes, with its phosphatase domain oriented towards the cytoplasm. The C-terminal 35 amino acids target the endoplasmic reticulum (Frangioni J. V. et al 1992). It could also regulate Endoplasmic reticulum functions such as protein synthesis, post translational protein modification, lipid synthesis and vesicular trafficking. In addition to dephosphorylating autophosphorylated insulin PTP-1B can dephosphorylate epidermal growth factor receptors (Tappia P. S et al 1991, Milarski K. L. et al 1993).

Autoantigens in Diabetes Mellitus

Insulin dependent diabetes mellitus (1DM) antibodies to glutamic acid decarboxylase (a 64-kDa autoantigen) are present in more than seventy percent of newly diagnosed patients and have been detected up to seven years before the onset of clinical disease (Baekkeskov S. et al 1990). The tyrosine phosphatase IA-2 (a 37/40-kDa antigen) was found in fifty four percent of newly diagnosed IDDM patients (Passini N. et al 1995, Payton M. A. et al 1995). Eighty eight percent of IDDM patients had antibodies to one or both of these antigens (Bonifacio E. et al 1995). A further antigen, insulinoma associated protein IA-2β (phogrin), which is an insulin granule membrane tyrosine phosphatase, has been observed in IDDM patients, it being the 37-kDa antigen and the IA-2 being the 40-kDa antigen (Lu J. et al 1996). Phogrin has a high homology with IA-2 protein. Fifty six percent of new onset IDDM patients had antibodies to phogrin (Kawasaki E. et al 1996).

In monozygotic twins the antibodies to IA-2, IA-2ic, GAD₆₅ and ICA were all predictive of diabetes development (Hawa M et al 1997). IA-2 and GAD antibody measurements when used in combination are as clinically useful as islet cell antibodies (ICA) measurements in predicting onset of diabetes (Borg. H. et al 1997). IA-2 antibodies seem to antedate the occurrence of IA-2β antibodies during the onset of type 1 diabetes (Bonifacio E. et al 1998).

Insulin binding antibodies were observed in eighteen percent of IDDM patients (Palmer J. et al 1983). The monosialoganglioside (GM2-1) is expressed at a one hundred fold higher level in pancreatic islets than in the remainder of the pancreas and it is hyperexpressed in mouse islets in the non obese diabetic mouse model (Dotta F. et al 1995). Antibodies to carboxypeptidase, which is a major protein of insulin secretory granules and helps convert proinsulin to insulin, were observed in a prediabetic patient (Castano L. et al 1991). A 38-kDa mitochondrial autoantigen was overexpressed in a newly diagnosed IDDM patient (Arden S. et al 1996).

At the onset of IDDM there is a dose dependent T cell response to IA-2 as measured form peripheral blood lymphocyte samples. The response does not correlate with age, sex or HLA-DR type (Dotta F. et al 1999). Four of five epitopes recognized by IA-2 human monoclonal antibodies were within the PTP like domain of IA-2, which is the most conserved region of tyrosine phosphatase proteins. The fifth epitope was within the juxtamembrane region of IA-2 (Kolm-Litty V. et al 2000).

IA-2 specific IFN-γ production, which is characteristic of a T cell response occurred in spleen cells of non obese diabetic mice (NOD), with development of diabetes a few weeks after the response peaked (Trembleau S. et al 2000).

Low dose streptozotocin induces an immunological, non antigen specific diabetes mellitus. On low dose streptozotocin administration the ICA 512 protein tyrosine phosphatase was decreased on the third day without induction of ICA-specific cytotoxic T cells. Toxic destruction of B cells stimulates recruitment of macrophages and production of monokines such as IL-1 and TNF-α, which have a cytopathic action on islet, cells (Li Z. et al 2000).

Macrophages stimulate T helper cells to release IFN-γ, the cytokine that is most likely responsible for induction of MHC Class 1 expression in the endocrine cells. IFN-γ was observed to induce islet cell MHC antigens and enhance streptozotocin induced diabetes in the CBA mouse model (Campbell L et al 1988).

Protein tyrosine phosphatase 1B levels were increased in obese non diabetics and further increased in obese diabetics. However PTP-1B activity per unit of PTP-1B protein was markedly reduced in obese non diabetics and in obese diabetics. Body mass index correlates with PTP-1B activity per unit of PTP-1B. Thus impaired PTP-1B activity may be pathogenic for insulin resistance (Cheung A. et al 1999). PTPase activity from subcellular fractions from nondiabetic subjects was increased and PTPase activity from obese non insulin diabetics was decreased (Ahmad F. et al 1997). Insulin increases tyrosine phosphatase activity in rat hepatoma (Hashimoto N. et al 1992) and rat L6 muscle cells (Kenner K. A. et al 1993). In the ob/ob mouse model levels of insulin receptor and tyrosine phosphatase PTP-1B decrease such that in muscle the ratio of PTP-1B to insulin receptors increases six fold compared with ob+control mice (Kennedy B. P. et al 2000).

Protein Tyrosine Phosphatase Catalysis

Peroxovanadium compounds are potent inhibitors of PNP-1B and examples such as mpV(2,6pdc) and mpV(pic) wee selective inhibitors, causing lesser inhibition of epidermal growth factor receptor (EGFR) dephophorylation (Posner B. I. et al 1994). The cysteine residue 215 and its surrounding residues from histidine 214 to arginine 221 reside in a hydrophobic pocket which recruits the phosphorylated tyrosine. The alanine 217 and glutamine 262 residues particularly contribute to the hydrophobicity. The cysteine residue is phosphorylated through a thiophosphate linkage during catalytic turnover and the phosphoenzyme intermediate is subsequently hydrolyzed by a water molecule, which attacks the just vacated leaving site. The cysteine residue (Cys215) forms a covalent cysteinyl phophoenzyme intermediate. The Asp 181 acts as a general acid to donate a proton to the phenolic/alcoholic oxygen and forms a network of hydrogen bonds to the phenolic oxygen of phosphotyrosine and a buried water molecule. The Asp residue is positioned to donate a proton to the tyrosine leaving group during the first hydrolysis step. The Asp residue also plays a role as a general base to activate a nucleophilic water molecule during the dephosphorylation step. An arginine plays a role in substrate recognition and transition state stabilization.

Use of a difluorophosphonate, substitution of a naphthalene ring for a phenyl ring in the phosphotyrosyl and addition of a hydroxyl in the naphthyl 4-position enhanced inhibitory potency of PIP-1B inhibitors (Burke T. R. et al 1996). The fluorines introduce hydrogen bonding interactions with the Asp 181-Phe 182 amide nitrogen, displace a water molecule and reduce the second phosphonate ionization constant (pK_a2). The hydroxyl group displaces two water molecules. 2-O-tyrosinyl malonate ethers, particularly when containing the difluoro substitution at the methylene bridge had enhanced efficiency as inhibitors (Burke T. R. et al 1996b). Benzylic and negatively charged substituents para to the hydrolyzable phosphate greatly increase affinity for PTPase Montserat J. et al 1996). A non phosphorous PTP inhibitor (2-(oxalyl-amino)-benzoic acid containing a basic nitrogen substituted in the tetrahydropyridine ring forms a salt bridge with Asp-48 of PTP-1B. Most other PTPases contain an asparagine amino acid at this position. This creates an efficacious selective competitive inhibitor of PTP-1B (Iversen L. G. et al 2000). A second aryl phosphate binding site close to the catalytic site has been identified and binds substrates such as phosphotyrosine and bis-(para-phosphophenyl)methane (BPPM) Puius Y. et al 1997). 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes were observed to act as efficacious inhibitors of PTPase (Wrobel J. et al 1999).

Polycations, including polyamines were observed to increase tyrosine phophatase activity (Tonks et al 1988). Conversely inhibition of polyamine synthesis by DFMO was found to increase tyrosine phosphatase and decrease tyrosine phosphorylation and adding putrescine to the medium diminished tyrosine phosphatase activity and increased tyrosine phophorylation (Oetken C. et al 1992).

Tyrosine Phosphatase Inhibitors/PPARα and PPARγ Partial Agonists/Partial Antagonists

Polyamines covalently bind to glutathione, however they also covalently bind with sterols and a spermine coupled cholesterol metabolite was identified in shark. It had potent central appetite suppressant effects in genetically obese mice (Zasloff M. et al 2001).

Prostaglandin J2 is an endogenous of PPARy and stimulates adipocyte differentiation (Wolf G 1996). The thiazolidinedione drugs are PPARy stimulators and may be useful in the treatment of the insulin resistance syndrome otherwise known as cardiovascular dymetabolic syndrome or syndrome X (Fujiwara T. et al 2000). PPARγ is not readily stimulated by fatty acids whereas PPARα in Liver and muscle is (Forman B. M. et al 1996).

Insulin Resistance Syndrome

The insulin resistance syndrome includes hyperinsulinemia, impaired glucose tolerance, hypertension, dyslipidemia, hyperuricemia, high fibrinogen levels and elevated plasminogen activator inhibitor-1 concentrations Heaven G. M. 1993). All these factors are associated with abdominal adiposity and are risk factors for coronary artery disease (Van Gaal L. F. et al 1999). Mitochondrial DNA damage and quantitative loss of mitochondria in preclinical diabetes overactivity of protein kinase C are key events, which precipitate insulin resistance.

Metabolic Effects of Chromium

As with low zinc consumption predisposing to IDDM, dietary chromium deficiency has been associated with development of atherosclerosis and glucose intolerance. Chromium concentration in human tissues decreases very considerably after the first two decades of life. Further chromium excretion by the kidney is increased following oral glucose loading (Schroeder H. A. 1967). Modern diets containing refined carbohydrates have been depleted of their chromium content Chromium concentrations in the hair of insulin dependent diabetic children were significantly lower than in controls (Hambidge K. M. et al 1968). Hepatic chromium concentrations were significantly decreased in diabetics and non significantly in atherosclerotic patients (Morgan J. M. 1972). Patients who died of cardiovascular diseases had lower aortic chromium concentrations than controls (Schroeder H. A. et al 1970). Human subjects with impaired glucose tolerance had significant improvement in impaired glucose tolerance, reduction of the exaggerated insulin response to a glucose load and reduction of serum cholesterol in response to chromium (Freiberg J. M. et al (1975). In spontaneously hypertensive rats chromium lead to a significant reduction in plasma glucose without significant effect on plasma insulin following intraperitoneal glucose challenge (Yoshimoto S. et al 1992). Chromium supplementation in diabetics improves glucose tolerance, decreases blood cholesterol and triglycerides, and increases high density lipoprotein (HDL) (Abraham A. S. et al 1992).

Plasma chromium levels and insulin levels after oral glucose loading were higher in obese controls than in lean controls, plasma chromium levels were similar in obese and lean insulin dependent diabetics (IDD), plasma chromium levels were higher in lean non insulin dependent diabetics (NIDD) than in controls. Chromium levels correlate with body mass index (BMI) and rise in the obese and in non insulin dependent diabetics (NIDD) in response to insulin resistance. Chromium excretion was significantly increased in lean insulin dependent diabetics (IDD) (Bale K. E. et al 1989).

Thus the major biochemical Components of Diabetes Mellitus include, Mitochondrial Dysfunction and energetics dysfunction, Impairment of Exocytosis of Insulin, Impaired Glucose Tolerance and Diminished Insulin Sensitivity with consequent Altered Carbohydrate and Fat Metabolism, Neuronal, Microvascular and Macrovascular Complications.

Atherosclerosis

In the hearts of patients having coronary artery disease the levels of mitochondrial DNA deletions M4977, M7436, M10,422 increase significantly and especially in left ventricle muscle, this area accumulating twenty seven times as many deletions as the left atrium (Corral-Debrinski M et al 1992). Ischemia causes a decrease in reduced glutathione and superoxide dismutase activity in heart (Ferrari R et al 1985). Hearts that have experienced acute myocardial infarction have elevated levels of mitochondrial DNA over controls though lesser elevation than occurs in coronary artery disease hearts (Ferrari R. et al 1996). Reduced pH and increase Pi result from accumulation of lactate and hydrolysis of ATP. Reduced pH and increased Pi downregulate contractility and cause akinesia of the ischemic zone. GF-109293X protects against hypoxia induced apoptosis in cardiac myocytes (Chen S. J. et al 1998).

The severity of clinical symptoms and survival time correlated with mitochondrial DNA defects in cardiomyopathy patients and hundreds of different DNA minicircles were observed (Ozawa T. et al 1995). Decreased activity levels of Complex I, III, IV and V occur in cardiomyopathy patients inheriting mutations or deletions of mitochondrial NDA (Marin-Garcia J. et al 1999) and depletion of mitochondrial DNA (Marin-Garcia J. et al 1988). Fifty percent of patients with hypertrophic cardiomyopathy were observed to have respiratory chain abnormalities (Zeviani M et al 1995). Alcohol, ischemia and adriamycin also cause cardiomyopathy with mitochondrial DNA deletions. Mitochondrial DNA defects occur less frequently in dilated cardiomyopathy as compared with hypertrophic cardiomyopathy (Arbustni E. 1998 and 2000). Coenzyme Q₁₀ has been found to be an effective therapy in cardiomyopathy and in the treatment of congestive heart failure (Langsjoen P. H. et al 1988).

In vascular smooth muscle PPARY activation inhibits matrix metallprotease-9 (MMP-9) expression and acivity Marx N. et al 1998). PPARY agonists stimulate uptake of oxidized low density lipoprotein by macrophages by increasing activity of the scavenger receptor CD36 (Tontonoz P. et al 1998). Troglizatone, rosiglitazone and 15-deoxy-PGJ-2 inhibited migration of vascular smoth muscle and migration of monocytes (Hsuch W. A. 2001). PPARα agonists such as fibrate drugs lowers the progression of aherosclerotic lesiions and PPARγ agonists such as troglitazone decreases intimal thickness in human carotid arteries (Law R et al 1998).

Stroke

Decreased levels of ATP, low pH, increase levels of intracellular glutamate, intracellular calcium ions and free radicals and protein kinase C activity occur during and post stroke. DNA fragmentation and oxidative damage occur (Chen J. et al 1997 and Cui J. et al 2000). Mitochondrial damage and cell death cause release of large quantities of redox metals locally in the area of the lesion. Endoplasmic reticulum releases calcium and this can be prevented in experimental stroke by dantrolene (Tasker R. C. et al 1998) Uric acid, a scavenger of peroxynitrite and hydroxyl radicals (Yu F. et al 1998), vitamin E (Tagami M. et al 1999) and estrogen (Goodman Y. et al 1996) can prevent apoptosis in stroke models. Putrescine, spermine and spermidine protected neurons in the CA1 layer of hippocampus and in the mediolateral body of striatum from degeneration after global ischemia in a gerbil strokemodel (Gilad G. etal 1991) and a syntetic polyamine N,N-di(4aminobutyl)-1-aminoindian being more protective against neuronal damagte post global forebrain ischemia in the gerbil (Gilad G. m., Gilad V. H. 1999). In a transgenic mouse overexpressing ornithine decarboxylase, the increased ornithine decarboxylase and resultatn induction of transcription factors c-Fos and zif-268 in the hippocampus were not damaging (Lukkarainen J et al 1995).

Presbycussis

Presbycussis results from mitochondrial DNA mutations such as the M3243 point mutation (Bonte C. A. et al 1997). Acetyl-carnitine and α-lipoic acid protected rats from developing hearing loss and diminished the quantity of mitochondrial DNA deletions which accumulated during aging (Seidman M. D. et al 2000). These compounds can be effective in upregulating cochlear mitochondrial function.

Cancer

Cell Division/Growth Factors

During the synthesis phase of cell division methionine is increasingly converted to homocysteine thiolactone, thioretinaco is converted to thioco and cobalamin is removed from binding to mitochondrial and endoplasmic reticulum membranes. Thus increased quantities of oxygen radical species are produced. Homocysteic aid is formed by oxidation of homocysteine thiolactone (McCully K. S. 1971). Homocysteic acid stimulates release of growth factors such as insulin like growth factor (Clopath P. et al 1976).

Depletion of Thioretinaco in Aging and Cancer

Depletion of thioretinaco from mitochondrial and microsomal membranes causes increased formation of oxygen radicals and their release within neoplastic and senescent cells (Olszewski A. J. et al 1993). Depletion of thioretinaco from mitochondrial and microsomal membranes causes; excessive homocysteine thiolactone synthesis; increased conversion of thioretinaco to thioco; inhibition of oxidative phosphorylation; and accumulation of toxic oxygen radical species McCully 1994a). Malignant cells accumulate homocysteine thiolactone. Deficient intracellular methionine and adenosyl methionine in malignant cells may result from excessive conversion of methionine to homocysteine lactone.

Metabolites and Retinoic Acid

Folic acid and riboflavin are required for the conversion of homocysteine to methionine. Reduced folate intake is associated with increased incidence of heart disease and stroke. Also DNA damage from hypomethylation occurs due to deficiency of adenosyl methionine.

Pro Carcinogenic and Anti Carcinogenic Compounds

Thioretinaco and thioretinamide are cytostatic in cultured malignant cells (McCully K. S. 1992). Homocysteine thiolactone causes fibrosis, necrosis, inflammation, squamous metaplasia, dysplasia, neoplasia, calcification and angiogenesis (McCully K. S. et al 1989, 1994a). Homocysteine induces apoptosis (Kruman L et al 2000). Secondary increase in homocysteine thiolactone leads to disulphide bond formation with amino acids. Homocysteic acid is produced by from oxidation of homocysteine thiolactone.

Neovascularization

Oxygen radicals cause tissue damage during neovascularization. Arteriosclerosis is observed in the new vasculature as cancer grows and invades. Atherogenesis is correlated with total homocysteine. Homocysteine is correlated with total cholesterol and low density lipoprotein (LDL)+high density lipoprotein (HDL) cholesterol McCully K. S. 1990) Increased synthesis of homocysteine thiolactone enhances atherogenesis because of thiolation of amino acids of apoB of low density lipoprotein producing aggregation and uptake of LDL by nacrophages.

ATP Formation and Oxygen Species Holding

Under normal circumstances the disulfonium form of thioretinaco, in the presence of ascorbate, is the electrophile that catalyzes reduction of radical oxygen species to water, concomitant with binding of ATP from the F1 complex 1994a,b). Binding of the oxygen anions of the proximal and terminal phosphates of ATP to the disulfonium complex releases ATP from the F1 binding site McCully K. S. 1994a). Adenosyl methionine formation and further formation of thioretinaco result from cleavage of the adenosyl triphosphate bond.

Toxic Models of Disease

Paraquat causes cell death in E. coli, which action is promoted by copper (Kohen R. et al 1985) and iron (Korbashi P. et al 1989). Paraquat causes single strand DNA breaks in mouse lymphoblasts (Ross W. E. et al 1979). Zinc displaced a redox metal and was effective in preventing paraquat toxicity in E. coli (Korbashi P. et. al.).

Histidine was successful in preventing MPP⁺ induced damage in E. coli (Haskel Y. et al). MPDP⁺, the monoamine oxidase metabolite of MPTP is also mutagenic (Cashman J. R. (1986). Poly (ADP-ribose) polymerase (PARP) activity is increased causing depletion of NAD⁺ and ATP. PARP inhibitors prevent MPTP induced damage in rodent substantia nigra (Zhang J et al 1995).

Rotenone induces Parkinosnism in animals and is an inhibitor of NADH dehydrogenase component of the electron transport chain Leach C. K. et al 1970, Erikson S. E. 1982, Phillips M. K. et al 1982). Diazoxide induces diabetes by inhibiting pancreatic glycerol phosphate dehydrogenase (MacDonald M. J. 1981 and thus inhibiting insulin release (Steinke J et al 1968).

Streptozotocin (N-methylnitrosocarbamoyl)Dglucosamine) which induces diabetes in animals, reduces DNA synthesis (Rosenkranz H. S. et al 1970) and induces DNA strand breakage (Reusser F 1971). Streptozotocin by causing DNA strand breaks increases poly (ADP-ribose) polymersase (PARP) activity resulting in NAD+ and ATP depletion (Pieper A A et al 1999, Cardinal J. W. et al 1999).

Oxidative metabolism of glucose is impaired after alloxan exposure (Borg L. A. et al 1979). Alloxan induces DNA strand breaks and poly (ADP-ribose) polymerase (PARP) activity and depletion of NAD (Yamamoto R et al 1981a, 1981b and Uchigata Y et al 1982). Alloxan causes oxidation of mitochondrial pyridine nucleotides (Frei B. et al 1985) with efflux of mitochondrial calcium. Alloxan lowers mitchondrial glutathione content of mitochondria (Boquist L. et al 1983). Alloxan inhibits glucose induced insulin release and activates the ATP sensitive K channel (Carroll P. B. et al 1994).

Contrast Media

Contrast media used in radiologic examinations include complexes of the following metals; trivalent gadolinium, iron, trivalent lanthanide (Aime S. et al 2002, Vilringer k, et al 1988 and Desreux J. F. et al 1988), manganese, technetium. Basic requirements for human use are that compound(s) are non ionic (Parvez Z et al 1991, Lloyd K. 1994), do not have COO groups, have OH groups in various positions around the molecule (Almen T. 1990), and are water-soluble. Secondary composition possibilities are that they may be monomers, dimers, trimers or tetramers (Morris T. 1993), may be incorporated into liposomes, will have low viscosity, will exhibit low osmolality (Matthai W. H. 1994), and have a particle size between 0.6 and 3 microns to avoid capillary embolism.

The toxicity of contrast media is caused by the following characteristics and actions; binding to proteins, enzyme inhibition, histamine release, alterations in electrolyte environment, hyperosmolality, prolonging whole blood clotting time in a dose dependent manner, inhibiting aggregation of platelets, opening of blood brain barrier, release of vasoactive substances from endothelial cells, activation of complement, alteration of Gibbs Donnan equilibrium, reduction of plasma calcium and magnesium, inhibition of cholinesterase, stimulation of prostaglandin release, immune system response, vasovagal response, platelet activation, alteration in secondary messenger systems, inhibition of clotting factors, lipid solubility and membrane alterations. The toxicity of iodine contrast media has caused interest in development of other metal complexes as alternatives for specific and broader uses in human and veterinary medicine.

Chain polyamine (Kim E. E. et al 1981) and polyazomacrocyclic polyamines (Sherry A. D. et al, Kiefer G. E. et al) have been used successfully as contrast media The biphenyl family of polyamines synthesized herein may have broad clinical applications as contrast media

An iron polyamine complex may be used in hepatic MRI imaging Zhang. XL. et al 2002, Chang D. et al 2002).

A manganese polyamine complex may be used as liver and pancreas contrast MRI agent amongst other uses (Gong J. et al 2002, Diehl S. J. et al 1999, Wang C. et al 1998). A liposome preparation of the complex can be used.

A gadolinium polyamine complex may be used for angiography, intraarticular examinations and hepatobiliary MRU It has no renal toxicity as compared with iodine media and can be used in patients who have had previous anaphylactic reactions to iodine media(Spinosa D. J. et al 2002).

A technetium polyamine complex may be used in detection and evaluation of myocardial ischemia patients. The chain polyamine triethylene tetramine has been used as a technetium gastric contrast media (Kim E. E. et al 1981).

SUMMARY OF THE INVENTION

The invention is a process for synthesizing polyamine compounds via a series of substitution reactions, optimizing the bioavailability and biological activities of the compounds, and their use as therapeutic agents for the treatment of Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease, Binswanger's disease, Olivopontine Cerebellar Degeneration, Lewy Body disease, Diabetes, Stroke, Atherosclerosis, Myocardial Ischemia, Cardiomyopathy, Nephropathy, Ischemia, Glaucoma, Presbycussis, Cancer, Osteoporosis, Rheimatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis and Toxin Exposure. Tetraamines and polyamines produced herein are compounds that act as bases and which can be prepared by the reaction of acyclic and cyclic amines or alkyl halides with a variety of substrates that will add to the amines or displace the halides. These tetraamines fall into a number of structural classes. These classes are: (1) predominately linear tetraamines and polyamines linked by 1,3-propylene and/or ethylene groups; (2) predominately branched tetraamines and polyamines linked by 1,3-propylene and/or ethylene groups; (3) cyclic polyamines linked by 1,3-propylene and/or ethylene groups; (4) combinations of linear, branched and cyclic polyamines linked by one or more 1,3-propylene and/or ethylene groups, (5) substituted polyamines, (6) polyamines derivatized to formtyrosine phosphatase inhibitor molecules and/or PPAR partial agonists—partial antagonists, with linear or branched chains attached and ((7) polyamine derivatives of 2,2′-diaminobiphenyl with linear or branched chains attached Further, the linked tetraamines may have one or more pendant alkyl, aryl cycloalkyl or heterocyclic moieties attached to the nitrogens.

Accordingly, in one aspect the invention is directed to compounds of the formula:

Wherein

• R₁ and R₂ may be the same or different and are hydrogen, alkyl, aryl, cycloalkyl, amino acid, glutathione, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, glutamate, succinate, acetyl-L-carnitine, co-enzyme Q, lazeroids, polyphenolic flavonoids, homocysteine, menaquinone, idebenone, dantrolene, —(CH₂)_n[XCH₂)_n]NH₂— wherein n=3-6 and X=nitrogen, sulfur, phosphorous or carbon, or heterocycle wherein R₁ and R₂ taken together are —(CH₂XCH₂)_n— wherein n=36 and X=nitrogen, sulfur, phosporous or carbon. R₃ and R₄ may be the same or different and are hydrogen, alkyl, aryl, cycloalkyl, amino acid, glutathione, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, glutamate, succinate, acetyl-L-carnitine, coenzyme Q, lazeroids, polyphenolic flavonoids, homocysteine, menaquinone, idebenone, dantrolene or heterocycle wherein R₃ and R₄ taken together are —(CH₂XCH₂)_n— wherein n=36 and X=nitrogen, sulfur, phosporous or carbon R₅ and R₆ may be the same or different and are hydrogen, alkyl, aryl, cycloalkyl, amino acid, glutathione, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, glutamate, succinate, acetyl-L-carnitine, co-enzyme Q, lazeroids, polyphenolic flavonoids, homocysteine, menaquinone, idebenone, dantrolene —(CH₂)_n[XCH₂)NH₂— wherein n=36 and X=nitrogen, sulfur, phosporous or carbon, or heterocycle wherein R₅ and R₆ taken together are —(CH₂XCH₂)_n— wherein n=3-6 and X=nitrogen, sulfur, phosporous or carbon. R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₃, and R₁₄, may be the same or different and are hydrogen, alkyl, aryl, cycloalkyl, amino acid, glutathione, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, glutamate, succinate, acetyl-L-carnitine, co-enzyme Q, lazeroids, polyphenolic flavonoids, homocysteine, menaquinone, idebenone, dantrolene —(CH₂)_n[XCH₂)_n]NH₂— wherein n=3-6 and X=nitrogen, sulfur, phosporous or carbon, or heterocycle wherein R₅ and Rr taken together are —(CH₂XCH₂)_n— wherein n=3-6 and X=nitrogen, sulfur, phosporous or carbon.

M, n, and p may be the same or different and are bridging groups of variable length from 3-12 carbons.

X₁ and X₂ may be the same or different and are nitrogen, sulfur, phosporous or carbon.

As used herein, “alkyl” has its conventional meaning as a straight chain or branched chain saturated hydrocarbyl residue such as methyl, ethyl, propyl, isopropyl, isobutyl, t-butyl, octyl, decyl and the like. The alkyl substituents of the invention are of 1 to 12 carbons which may be substituted with 1 to 2 substitutents.

“Cycloalkyl” refers to a cyclic allyl structure containing 3 to 25 carbon atoms. The cyclic structure may have alkyl substituents at any position. Representative groups include cyclopropyl, cyclopentyl, cyclohexyl, 4-methylcyclohexyl, cyclooctyl and the like.

“Aryl” refers to aromatic ring systems such as phenyl, naphthyl, pyridyl, quinolyl, indolyl and the like; aryl alkyl refers to aryl residues linked to the position indicated through an alkyl residue.

“Heterocycle” refers to ringed moieties with rings of 3-12 atoms and which contain nitrogen, sulfur, phosphorus or oxygen.

As shown from the above structures, examples include derivatives of 1,3-bis-[(2′-aminoethyl)-amino]propane (referred to hereafter as 2,3,2-tetraamine); 1,4-bis-[(3′-aminopropyl) amino]butane (referred to as 3,3,3-tetraamine); and 1,4,8,11-Tetraazacyclotetradecane (cyclam). Specific examples include N, N′,N″,N′″-tetramethyl 2,3,2-tetramine; N,N′″-diethyl 2,3,2-tetramine; N,N′″-Dipiperidyl-2,3,2-tetramine, N,N′,N″,N′″-tetramethylcyclam and N,N′,N″,N′″-tetraadamantylcyclam.

Particularly preferred embodiments of R₁ and R₄ are piperidine, piperizine, or adamantane. In this embodiment, N₁ and N₄ are part of the piperidine or piperazine rings while in the adamantane case, N₁ and N₄ are appended from the rings.

It will be understood that the compounds of 1 and 2, since they contain a basic amine group, form salts with non-toxic acids and such salts are included within the scope of this invention. These salts may enhance the pharmaceutical application of the compounds. Representative of such salts are the hydrochloride, hydrobromide, sulfate, phosphate, acetate, lactate, glutamate, succinate, propionate, tartrate, salicylate, citrate and bicarbonate.

There are three structural motifs that are being exploited in this invention. 1,3-bis-[(2′-aminoethyl)-amino]propane (2,3,2-tetramine) and its derivatives are tetramines that are known to have a large number of physiological actions. They are well known binders of metal ions and form very stable complexes with a variety of transition metals. Secondly, polyazamacrocycles such as 1,4,8,11-tetramethyl-1,4,8,11-tetrazacyclotetradecane (cyclam) are of considerable interest due to their ability to form strong complexes with transition metals such as copper, cobalt, iron, zinc, cadmium, manganese and chromium.

Accordingly, in a second aspect the invention is directed to compounds of the formula:

Wherein

• R₁-R₄ may be the same or different and are hydrogen, alkyl, aryl, cycloalkyl, hydroxyl, thiol, amino acid, glutathione, phosphate, phosphonates, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, succinate, acetyl-L-carnitine, coenzyme Q, lazeroids, polyphenolic flavonoids, —(CH₂)_n[XCH₂)_n]NH₂— wherin n=3-12 and X=nitrogen, sulfur, phosporous or carbon, or heterocycle wherein R₁ and R₂ taken together are —(CH₂XCH₂)_n— wherein n=3-12 and X=nitrogen, sulfur, phosphorous or carbon. R₅ and R₅ may be the same or different and are hydrogen, alkyl, aryl, cycloalkyl, hydroxyl, thiol, amino acid, glutathione, phosphate, phosphontes, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, succinate, acetyl-L-carnitine, co-enzyme Q, lazeroids, polyphenolic flavonoids, or heterocycle wherein R₃ and R₄ taken together are —(CH₂XCH₂)_n— wherein n=3-12 and X=nitrogen, sulfur, phosphorous or carbon. R₇ and R₈ may be the same or different and are hydrogen, alkyl, aryl, cycloalkyl, hydroxyl, thiol, amino acid, glutathione, phosphate, phosphonate, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, succinate, acetyl-L-carnitine, co-enzyme Q, lazeroids, polyphenolic flavonoids, —(CH₂)_n[XCH₂)_n]NH₂— wherin n=3-12 and X=nitrogen, sulfur, phosporous or carbon, or heterocycle wherin R₅ and R₆ taken together are —(CH₂XCH₂)_n— wherin n=3-12 and X=nitrogen, sulfur, phosphorous or carbon. R₉ is hydrogen, alkyl, aryl, cycloalkyl, hydroxyl, thiol, amino acid, glutathione, phosphate, phosphonate, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, succinate, acetyl-L-carnitine, co-enzyme Q, lazeroids, polyphenolic flavonoids, —(CH₂)_n[XCH₂)_n]NH₂— wherin n=3-12 and X=nitrogen, sulfur, phosporous or carbon, or heterocycle wherein R₅ and R₆ taken together are {CH₂XCH₂)_n— wherein n=3-12 and X=nitrogen, sulfur, phosphorous or carbon.

X₁-X₄ may be the same or different and are nitrogen, sulfur, phosphorous or carbon.

wherein

• R₁-R₄ may be the same or different and are hydrogen, alkyl, aryl, cycloalkyl, hydroxyl, thiol, amino acid, pyridine, pyrazole, 3,5-dimethylpyrazole, imidazole, quinoline, phenol, 4-X-phenol and 5-X-phenol where X=chloro, bromo, nitro, methyl, ethyl, methoxy, amino, hydroxy; glutathione, phosphate, phosphonates, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, succinate, acetyl-L-carnitine, co-enzyme Q, lazeroids, polyphenolic flavonoids, —(CH₂)_n[XCH₂)_n]NH₂— wherin n=3-6 and X=nitrogen, sulfur, phosporous or carbon, or heterocycle wherin R₁ and R₂ taken together are —(CH₂XCH₂)_n— wherin n=3-6 and X=nitrogen, sulfur, phosphorous or carbon. R₅ and R₅ may be the same or different and are hydrogen, alkyl, aryl, cycloalkyl, hydroxyl, thiol, amino acid, pyridine, pyrazole, 3,5 dimethylpyrazole, imidazole, quinoline, phenol, 4-X-phenol and 5-X-phenol where X=chloro, bromo, nitro, methyl, ethyl, methoxy, amino, hydroxy; glutathione, phosphate, phosphontes, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, succinate, acetyl-L-carnitine, co-enzyme Q, lazeroids, polyphenolic flavonoids, or heterocycle wherin R₃ and R₄ taken together are —(CH₂XCH₂)_n— wherin n=3-6 and X=nitrogen, sulfur, phosphorous or carbon.
• R₅-R₁₂ may be the same or different and are hydrogen, alkyl, aryl, cycloalkyl, hydroxyl, thiol, amino acid, pyridine, pyrazole, imidazole, quinoline, phenol, 4-X-phenol and 5-X-phenol where X=chloro, bromo, nitro, methyl, ethyl, methoxy, amino, hydroxy; glutathione, phosphate, phosphonate, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, 1-carotene, meanadione, succinate, acetyl-L-carnitine, co-enzyme Q, lazeroids, polyphenolic flavonoids, —(CH₂)_n[XCH₂)_n]NH₂— wherin n=3-6 and X=nitrogen, sulfur, phosporous or coon, or heterocycle wherin R₅ and & taken together are —(CH₂XCH₂)_n— wherin n=3-6 and X=nitrogen, sulfur, phosphorous or carbon.
• N is an integer with values from 0-10.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1-41 depict reaction schemes for the preparation of a variety of intermediates and the subsequent polyamines described in the invention and FIGS. 42-46 depict the effect of polyamines on toxin induced bacterial inactivation as follows:

FIG. 1 Route of Synthesis of 1,3-bis-[(2′-aminoethyl)-amino]propane and analogous compounds

FIG. 2 Route of Synthesis of [2-methylethylamino)ethyl](3-{[2-(methylamino)ethyl]amino}propyl)amine and analogous compounds

FIG. 3 Route of Synthesis of (2-piperidylethyl)-{3-[(2-piperidylethyl)amino]propyl}amine and analogous compounds

FIG. 4 Route of Synthesis of (2-piperazinylethyl){3-[(2-piperazinylethyl)amino]propyl}amine and analogous compounds

FIG. 5 (2-aminoethyl)(3-[(2-aminoethyl)methylamino]propyl}methylamine and analogous compounds

FIG. 6 [2-(bicyclo[3.3.1]non-3-ylamino)ethyl](3-{2-(bicyclo[3.3.1]non-3-ylamino)ethyl]amino}propyl)amine and analogous compounds

FIG. 7 (2-aminoethyl){3-[(2-aminoethyl)amino]-1-methylbutyl}amine and analogous compounds

FIG. 8 (2-pyridylmethyl){3-[(2-pyridylmethyl)amino]propyl}amine and analogous compounds

FIG. 9 methyl(3-[methyl(2-pyridylmethyl)amino]propyl}(2-pyridylmethyl)amine and analogous compounds

FIG. 10 [2-dimethylamino)ethyl](3-{[2-(dimethylamino)ethyl]methylamino}propyl)methylamine and analogous compounds

FIG. 11 2-[3-2-aminoethylthio)propylthio]ethylamine and analogous compounds

FIG. 12 1,4,8,11-tetraaza-1,4,8,11-tetramethylcyclotetradecane and analogous compounds

FIG. 13 1,4,8,11-tetraaza-1,4,8,11-tetra(2-piperidylethyl)cyclotetradecane and analogous compounds

FIG. 14 1,4,8,11-tetraaza-1,4,8,11-tetrabicyclo[3.3.1]non-3-ylcyclotetradecane and analogous compounds

FIG. 15 1,4,8,11-tetraaza-1,4,8,11-tetraethylcyclotetradecane and analogous compounds

FIG. 16 N,N′-(2′-dimethylphosphinoethyl)-propylenediamine and analagous compounds

FIG. 17 3-(3-(2-aminoethoxy)propoxy)propylamine and analagous compounds

FIG. 18 Vanadyl 2,3,2-Tetramine and analagous compounds

FIG. 19 Chromium 2,3,2-Tetramine and analagous compounds

FIG. 20 Vanadyl (2-piperidylethyl)-{3-[(2-piperidylethyl)amino]propyl}amine)(Cl)₂ and analagous compounds

FIG. 21 Chromium (2-piperidylethyl)-{3-[(2-piperidylethyl)amino]propyl}amine (Cl)₂]Cl and analagous compounds

FIG. 22 Vanadyl (1,4,8,11-tetraaza-1,4,8,11-tetrabicyclo[3.3.1]non-3-ylcyclotetra decane) (Cl)₂ and analagous compounds

FIG. 23 (Chromium 1,4,8,11-tetraaza-1,4,8,11-tetrabicyclo[3.3.1]non-3-ylcyclotetradecane(Cl)₂]Cl and analagous compounds

FIG. 24 p-(Phosphonomethyl)-DL-phenylalanine-Butylamine salt and analagous compounds

FIG. 25 2-amino-N(2-{[3-(2-amino-3-4-phosphonomethylphenyl)propanolylamino]ethyl)amino)propyl]amino}ethyl-3-(4-phosphonomethylphenyl)propamide and analagous compounds

FIG. 26 2,2′-diamino (bis-N,N′-pyridylmethyl)biphenyl and analagous compounds

FIG. 27 2,2′-diamino(bis-N,N-pyridylmethyl)-6,6′-dimethylbiphenyl and analagous compounds

FIG. 28 2,2′-diamino (bis-N,N′-quinilylmethyl)biphenyl and analagous compounds

FIG. 29 [(3,5-dimethylpyrazolyl)methyl][2-2-{[(3,5dimethylpyrazolyl) methyl]amino}phenyl)phenyl]amine and analagous compounds

FIG. 30 2-{[(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol and analagous compounds

FIG. 31 2-({[2-2-{[2hydroxyphenyl)methyl]amino}phenyl)phenyl]amino}methyl)phenol and analagous compounds

FIG. 32 4-methyl-2-{[(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol and analagous compounds

FIG. 33 3-nitro-2-{([(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol and analagous compounds

FIG. 34 4-chloro-2-{[(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol and analagous compounds

FIG. 35 2,amino-3-(-(4phosphonomethylphenyl)-N-2-{-2-[benzylamio]phenyl}phenyl)propamide and analagous compounds

FIG. 36 Manganese (2,2diamino (bis-N,N′-quinilylmethyl)biphenyl)(Cl)₂ and analagous compounds

FIG. 37 Iron (4-chloro-2-{[(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol)(Cl)₂]Cl and analagous compounds

FIG. 38 Vanadium (2,2′-diamino(bis-N,N′-pyridylmethyl)biphenyl)Cl₂ and analagous compounds

FIG. 39 Gadolinium (2,2′-diamino(bis-N,N′-pyridylmethyl)biphenyl)Cl₂]Cl and analagous compounds

FIG. 40 Chromium (2-({[2-(2-{[2-hydroxyphenyl)methyl]amino}phenyl) phenyl]amino}methyl)phenol)Cl)₂]Cl and analagous compounds

FIG. 41 Schematic of 2,3,2, tetramine structure, 1,3-bis-[(2′-aminoethyl)-amino]propane

FIG. 42 Effect of Spermidine on Diazoxide-induced Bacterial Inactivation

FIG. 43 Effect of 2,3,2-piperidine on Diazoxide-induced Bacterial Inactivation

FIG. 44 Effect of 2,3,2-pyridine on Diazoxide-Induced Bacterial inactivation

FIG. 45 Effect of 2,3,2diCH₃ on Diazoxide-Induced Bacterial Inactivation

FIG. 46 Effect of Cyclam Adamantane on Diazoxide-Induced Bacterial Inactivation

DESCRIPTION OF PREFERRED EMBODIMENTS

Heats of Formation

Among the reasons for the selection of compounds to be used for these formulations are the results of a series of calculations using heats of formations of the molecules. The relative stables of the compounds were determined in order to predict which would lead to the most stable metal complexes when they react with metals such as copper, cobalt, iron, zinc, cadmium, manganese and chromium These metals are of particular interest due to their importance in neurological and other diseases.

Heats of formation (ΔH°) are calculated by looking at the formation of a compound from its constituent atoms. The lower the heat of formation, the more stable is the compound. The assumption in this computational work is that the calculated heats of formation for the complexes will correlate with the ability of the organic compound to complex with metal ions in biological systems. The more strongly the binding occurs, the more likely it is that the organic molecule will interact with the metal ion of choice. There are other factors that enter into the actual binding ability of the organic molecules, but heats of formation help suggest how different organic molecules might behave. By varying the organic molecules, the heats of formation for the complexes can be compared and correlations between the stability of the complexes and the structure of the complexes can be made. The relative stabilities of a representative survey of organic compounds is shown in Table I while the heats of formation for the metal complexes are shown in Tables II-VIII.

TABLE I

Heats of Formation of Organic Compounds

Compound

ΔH° (Kcal/mol)

2,3,2-tetramine

−18.24

2,2,2-tetramine

−17.09

3,3,3-tetramine

−32.70

2,3,2-methylated on N1/N4

−13.81

2,3,2-methylated on N2/N3

−10.35

2,3,2-piperidine

−32.47

2,3,2-piperizine

4.33

2,3,2-tetra sulfur

−26.25

cyclam

−15.65

cyclam-methylated

18.73

cyclam-adamantane

−40.02

TABLE II

Heats of Formation of Copper Complexes

Compound

ΔH° (Kcal/mol)

Cu 2,3,2-tetramine

244.10

Cu 2,2,2-tetramine

252.36

Cu 3,3,3-tetramine

224.16

Cu 2,3,2-methylated on N1/N4

243.98

Cu 2,3,2-methylated on N2/N3

241.42

Cu 2,3,2-isopropyl on N1/N4

207.69

Cu 2,3,2-isopropyl on N2/N3

250.17

Cu 2,3,2-dibenzyl on N2/N3

314.08

Cu 2,3,2-tetramethyl

273.85

Cu 2,3,2-tetraisopropyl

229.83

Cu 2,3,2-benzylated

380.10

Cu 2,3,2-piperidine

255.10

Cu 2,3,2-piperizine

288.68

Cu 2,3,2-adamantane

269.53

Cu 2,3,2-methyls on carbons 5/7

227.45

Cu 2,3,2-tetra sulfur

210.42

Cu cyclam

260.20

Cu cyclam-methylated

298.97

Cu cyclam-benzylated

405.60

Cu cyclam-adamantane

254.55

Cu cyclam-isopropyl

271.59

Cu cyclam-S4

207.15

Cu cyclen

285.10

Cu cyclam 3,3,3

245.28

TABLE III

Heats of Formation of Iron Complexes

Compound

ΔH° (Kcal/mol)

Fe 2,3,2

12.16

Fe 2,2,2

37.16

Fe 3,3,3

−1.39

Fe 2,3,2-methylated on N1/N4

−8.19

Fe 2,3,2-piperidine

−54.23

Fe 2,3,2-piperizine

−18.51

Fe 2,3,2-adamantane

−19.16

Fe 2,3,2-methyls on carbons 5/7

7.99

Fe 2,3,2-tetra sulfur

87.39

Fe cyclam

−5.75

Fe cyclam-methylated

−69.53

Fe cyclam-adamantane

−92.82

Fe cyclam-isopropyl

−83.02

Fe cyclam-S4

137.13

Fe cyclen

17.76

Fe cyclam 3,3,3

−31.73

TABLE IV

Heats of Formation of Zinc Complexes

Compound

ΔH° (Kcal/mol)

Zn 2,3,2

355.75

Zn 2,2,2

352.45

Zn 3,3,3

328.73

Zn 2,3,2-methylated on N1/N4

336.55

Zn 2,3,2-isopropyl on N1/N4

316.18

Zn 2,3,2-isopropyl on N2/N3

330.81

Zn 2,3,2-tetramethyl

351.00

Zn 2,3,2-benzlyated

478.96

Zn 2,3,2-piperizine

351.70

Zn 2,3,2-methyls on carbons 5/7

342.21

Zn 2,3,2-tetra sulfur

329.15

Zn cyclam

358.25

Zn cyclam-methylated

388.64

Zn cyclam-benzylated

485.39

Zn cyclam-adamantane

347.52

Zn cyclam-isopropyl

330.81

Zn cyclam-S4

339.04

Zn cyclam 3,3,3

351.89

TABLE V

Heats of Formation of Manganese Complexes

Compound

ΔH° (Kcal/mol)

Mn 2,3,2

266.79

Mn 2,2,2

235.44

Mn 3,3,3

194.42

Mh 2,3,2-tetra sulfur

264.50

Mn cyclam

215.97

Mn cyclam-methylated

198.40

Mn cyclam-S4

248.57

TABLE VI

Heats of Formation of Cobalt Complexes

Compound

ΔH° (Kcal/mol)

Co 2,3,2

−1250.81

Co 2,2,2

−1236.41

Co 3,3,3

−1265.92

Co 2,3,2-methylated on N1/N4

−1269.13

Co 2,3,2-piperidine

−1300.69

Co 2,3,2-adamantane

−1250.92

Co 2,3,2-methyls on carbons 5/7

−1268.45

Co 2,3,2-tetra sulfur

−1258.52

Co cyclam

−1187.9

Co cyclam-methylated

−1265.64

Co cyclam-isopropyl

Co cyclam-S4

−1265.56

TABLE VII

Heats of Formation of Cadmium Complexes

Compound

ΔH° (Kcal/mol)

Cd 2,3,2

393.21

Cd 2,2,2

401.00

Cd 3,3,3

382.04

Cd 2,3,2-isopropyl on N1/N4

366.86

Cd 2,3,2-isopropyl on N2/N3

376.40

Cd 2,3,2-piperidine

374.06

Cd 2,3,2-adamantane

354.51

Cd 2,3,2-tetra sulfur

357.79

Cd cyclam

411.95

Cd cyclam-isopropyl

376.40

Cd cyclam-S4

356.13

TABLE VIII

Heats of Formation of Chromium Complexes

Compound

ΔH° (Kcal/mol)

Cr 2,3,2

398.73

Cr 2,3,2-isopropyl on N1/N4

379.87

Cr 2,3,2-piperidine

403.22

Cr cyclam

399.99

Cr cyclam-isopropyl

430.05

This tabular data can be analyzed by comparing the various structural features of the molecules as in examples 19 to 24 below.

Preparation of the Invention Compounds

There are numerous compounds described in the invention but in general, the invention compounds are obtained by converting the starting di- or tetramine of the formula:

A variety of reactions were used to prepare the compounds. Compound 1 was prepared via a nucleophilic substitution reaction followed by conversion of the free amine to its HCl salt. The amine acts as the nucleophile in displacing the di-alkyl halide, a reaction of general utility. Compound 2 also involved a nucleophilic substitution reaction, this time done in basic solution with a protection/deprotection sequence also involved in the synthesis. The use of acetyl groups to protect the amines could be exploited to alkylate tetramines.

Compounds 3 and 4 were synthesized by having 1,3-diaminopropane serve as the nucleophile with displacement occurring on the α carbon to the piperidine or piperizine. The β position is particularly susceptible to nucleophilic attack in molecules of this type. Other heterocyclic moieties could be added in similar fashion starting from the appropriate Methyl heterocycle in this fashion.

The theme of using amines to attack alkyl halides in nucleophilic substitution reactions was also exploited in the formation of 6 and 14. The 1-position in the bromoadamantane is much more reactive than expected and so the adamantane moiety could be added to numerous amines in this fashion Compound 7 involves a novel preparation of an existing compound as we reversed the nature of the nucleophile and the electrophile to lead to high yields of the product. In the case described, the 1,3-substituted portion is the alkyl halide while the amine is used to form the terminal nitrogens.

Compounds 8 and 9 were prepared using substitution reactions rather than the previously reported (for 8) imine formation reaction followed by a reduction. The α-carbon on the pyridine ring is extremely reactive due to resonance stabilization of any intermediate formed. This is a general approach and numerous other aromatic heterocycles could be added in this fashion.

We have continued the take advantage of nucleophilic substitution reactions to prepare 11 with the electrophilic 2-chloroethylamine. Once again, this scheme illustrates the extreme reactivity of the carbon on amines when used to do substitution reactions. 2-chloroethylamine could be added to many amines to form other tetraamines including many that are not symmetrical.

Compound 13 was prepared in a fashion similar to that used to synthesize 3. The staring amine here is the macrocyclic cyclam This reaction illustrates the power of using macrocycles in these schemes as the substitution led cleanly to the tetramine. Compound 15 was prepared under strongly basic conditions using the anion of the cyclam as the nucleophile attacking an alkyl halide. Certainly any primary alkyl halide could be substituted in this sequence. Phosphine also can be incorporated into these molecules as been done for Compound 16. This molecule was prepared via the use of an addition/reduction sequence starting with an amine. This reaction could be used on any number of amines covered in this patent. This was done for the preparation of compound 17 where oxygens were incorporated into the internal positions of the molecule.

Compounds 1-17 can be used to make metal complexes. Examples include the preparation of the vanadium complexes 18, 20 and 22 where 2,3,2-tetramine is converted into their vanadium complexes by treatment with a vanadium precursor. Compounds 19, 21 and 23 were prepared in similar fashion starting with a chromium precursor. Any number of metal complexes such as copper, cobalt, iron, manganese could be prepared from any of the compounds 1-17 by treating these compounds with the appropriate metal salt followed by isolation of the metal complex.

Compound 24 is a tyrosine phosphatase inhibitor molecule that was prepared in this work. It has also been attached to polyamines via a protection-substitution-deprotection sequence resulting in islation of 25 and 35. These novel compounds include both the polyamine backbone portion along with the tyrosine-phosphate portion.

Compound 26 incorporates the biphenyl moiety into a polyamine compound This compound is prepared by a nucleophilic substitution reaction of the biphenyl precursor with the chloromethylated pyridine. The a position of the heterocyclic pyridine is particularly reactive and we take advantage of this fact in the synthesis of 26.

The related compound 27 was prepared in a two step process by first forming the imine that is isolated and purified followed by reduction. This two step reaction sequence is also used to prepare 28, 30, 31, 32, 33 and 34 from the appropriate substituted heterocycle and the substituted biphenyl. Large numbers of other imines could be formed and converted to the desired amines using a similar sequence of steps.

Compound 29 was synthesized by an unusual nucleophilic substitution using a hydroxy group as the leaving group from a hydroxymethylpyrazole in its reaction a substituted biphenyl.

Compounds 36-40 are metal complexes prepared from the compounds described above. These Mn, Fe, V, Gd and Cr complexes are representative of the utility of compounds 24-35 as electron donors to metal ions. Numerous other metal complexes could be prepared.

(where A and B equal hydrogen or alkyl and m, n, and p may be the same or different) to the corresponding N-substituted compound by treating these compounds with an alkyl halide under conditions that affect the conversion.

• R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₉, R₉, R₁₀, R₁₁, R₁₂, R₁₃, and R₁₄, may be different and are hydrogen, alkyl, aryl, cycloalkyl, amino acid, glutathione, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, glutamate, succinate, acetyl-L-carnitine, co-enzyme Q, lazeroids, polyphenolic flavonoids, homocysteine, menaquinone, idebenone, dantrolene —(CH₂)_n[XCH₂)_n]NH₂— wherein n=3-6 and X=nitrogen, sulfur, phosphorous or carbon, or heterocycle wherein R₅ and R₆ taken together are —(CH₂XCH₂)_n— wherein n=3-6 and X=nitrogen, sulfur, phosporous or carbon.
• M, n, and p may be the same or different and are bridging groups of variable length from 3-12 carbons.
• X₁ and X₂ may be the same or different and are nitrogen, sulfur, phosporous or carbon

Accordingly, in a second aspect the invention is directed to compounds of the formula:

Wherein

• R₁-R₄ may be the same or different and are hydrogen, alkyl aryl, cycloalkyl, hydroxyl, thiol, amino acid, glutathione, phosphate, phosphonates, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, succinate, acetyl-L-carnitine, co-enzyme Q, lazeroids, polyphenolic flavonoids, —(CH₂)_n[CH₂)_n]NH₂— wherin n=3-12 and X=nitrogen, sulfur, phosporous or carbon, or heterocycle wherin R₁ and R₂ taken together are —(CH₂XCH₂)_n— wherin n=3-12 and X=nitrogen, sulfur, phosphorous or carbon. R₅ and R₅ may be the same or different and are hydrogen, alkyl, aryl, cycloalkyl, hydroxyl, thiol, amino acid, glutathione, phosphate, phosphontes, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, succinate, acetyl-L-carnitine, enzyme Q, lazeroids, polyphenolic flavonoids, or heterocycle wherin R₃ and R₄ taken together are —(CH₂XCH₂)_n— wherin n=3-12 and X=nitrogen, sulfur, phosphorous or carbon.
• R₇ and R₈ may be the same or different and are hydrogen, alkyl, aryl, cycloalkyl, hydroxyl, thiol, amino acid, glutathione, phosphate, phosphonate, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, succinate, acetyl-L-carnitine, co-enzyme Q, lazeroids, polyphenolic flavonoids, —(CH₂)_n[XCH₂)_n]NH₂— wherin n=3-12 and X=nitrogen, sulfur, phosporous or carbon, or heterocycle wherin R₅ and R₆ taken together are —(CH₂XCH₂)_n— wherin n=3-12 and X=nitrogen, sulfur, phosphorous or carbon. R₉ is hydrogen, alkyl, aryl, cycloakyl, hydroxyl, thiol, amino acid, glutathione, phosphate, phosphonate, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, succinate, acetyl-L-carnitine, co-enzyme Q, lazeroids, polyphenolic flavonoids, —(CH₂)_n[XCH₂)_n]NH₂— wherin n=3-12 and X=nitrogen, sulfur, phosporous or carbon, or heterocycle wherin R₅ and R₆ taken together are —(CH₂XCH₂)_n— wherin n=3-12 and X=nitrogen, sulfur, phosphorous or carbon. X₁-X₄ may be the same or different and are nitrogen, sulfur, phosphorous or carbon. or

  
  
  

  Wherein

• R₁-R₄ may be the same or different and are hydrogen, alkyl, aryl, cycloalkyl, hydroxyl, thiol, amino acid, pyridine, pyrazole, 3,5-dimethylpyrazole, imidazole, quinoline, phenol, 4-X-phenol and 5-X-phenol where X=chloro, bromo, nitro, methyl, ethyl, methoxy, amino, hydroxy, glutathione, phosphate, phosphonates, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, succinate, acetyl-L-carnitine, co-enzyme Q, lazeroids, polyphenolic flavonoids, —(CH₂)_n[XCH₂)_n]NH₂— wherin n=3-6 and X=nitrogen, sulfur, phosporous or carbon, or heterocycle wherin R₁ and R₂ taken together are —(CH₂XCH₂)_n— wherin n=3-6 and X=nitrogen, sulfur, phosphorous or carbon. R₅ and R₅ may be the same or different and are hydrogen, alkyl, aryl, cycloalkyl, hydroxyl, thiol, amino acid, pyridine, pyrazole, 3,5-dimethylpyrazole, imidazole, quinoline, phenol, 4-X-phenol and 5-X-phenol where X=chloro, bromo, nitro, methyl, ethyl, methoxy, amino, hydroxy; glutathione, phosphate, phosphontes, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, succinate, acetyl-L-carnitine, co-enzyme Q, lazeroids, polyphenolic flavonoids, or heterocycle wherin R₃ and R₄ taken together are —(CH₂XCH₂)_n— wherin n=3-6 and X=nitrogen, sulfur, phosphorous or carbon. R₅-R₁₂ may be the same or different and are hydrogen, alkyl, aryl, cycloalkyl, hydroxyl, thiol, amino acid, pyridine, pyrazole, imidazole, quinoline, phenol, 4-X-phenol and 5-X-phenol where X=chloro, bromo, nitro, methyl, ethyl, methoxy, amino, hydroxy; glutathione, phosphate, phosphonate, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin E, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, succinate, acetyl-L-carnitine, co-enzyme Q, lazeroids, polyphenolic flavonoids, —(CH₂)_n[XCH₂)_n]NH₂— wherin n=3-6 and X=nitrogen, sulfur, phosporous or carbon, or heterocycle wherin R₅ and R₆ taken together are —(CH₂XCH₂)_n— wherin n=3-6 and X=nitrogen, sulfur, phosphorous or carbon.
• N is an integer with values from 0-10.

There are also instances where some forms of 2,3,2-tetramine need to be protected prior to adding on the various groups as is true for 2 and 6. For the cyclam type molecules, nucleophilic substitution reactions were generally used to prepare the compounds (compounds 10-15).

Compounds 2, 3, 4, 6, 9, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 32, 33, 34, 35, 36, 37, 38, 39, 40 are prepared in this invention for the first time. Of the known compounds described here, most (5, 7, 8, 10, 11, 12, 15, 26, 30, 31) have been prepared in a fashion significantly different than that found in the literature. In addition, many of the compounds covered in the invention but not used as examples have not been prepared elsewhere and will be prepared as part of this invention for the first time.

The base compound 1,3-bis-[(2′-aminoethyl)-amino]propane, 1, was prepared in a fashion similar to that found in the literature (Van Alphen J. 1936). However, in the original literature preparation, an impurity was found that significantly reduced the purity of the product. Subsequent preparations have taken a number of tacks to lead to a pure product. We have eliminated this problem by developing a purification strategy that works through the hydrochloride salt that leads to a single product of very high purity.

In order to prepare the novel compound 2, ([2{methylethylamino)ethyl](3-{[2-(methylamino)ethyl]amino}propyl)amine), protection of the more reactive terminal nitrogens 1 and 4 as their acetyl derivatives was performed prior to methylation of nitrogens 2 and 3. Deprotection of the acetyl groups with KOH led to the desired compound.

Compounds 3 ((2-piperidylethyl)-{3-[(2-piperidylethyl)amino]propyl}amine) and 4 ((2-piperazinylethyl)-{3-[(2-piperazinylethyl)amino]propyl}amine) were made in similar fashion through the nucleophilic substitution reaction of 1,3-diaminopropane with 1-(2-chloroethyl)piperidine (to give 3) or 1-(2-chloroethyl)piperizine (to give 4). Numerous other tetramines are accessible through similar reactions where the nature of the amine is varied.

(2-aminoethyl){3-[(2-aminoethyl)methylamino]propyl}methylamine, 5, is a known compound (Barefield E. K et al 1976) but was prepared in a novel way here. The physical properties of our compound do not match those found in the literature but the NMR data in the literature in no way fits the structure of the compound while our NMR and mass spectral data are consistent with the formulation.

Compound 6, [2-bicyclo[3.3.1]non-3-ylamino)ethyl](3-{2-bicyclo[3.3.1]non-3-ylamino)ethyl]amino}propyl)amine and compound 14, 1,4,8,11-tetraaza-1,4,8,11-tetrabicyclo[3.3.1]non-3-ylcyclotetradecane were prepared in a similar way. Direct amination (Krumkalns E. V. et al 1968) of 1-bromoadamantane with the appropriate amine led to the pure products.

Compound 7, (2-aminoethyl){3-[(2-aminoethyl)amino]-1-methylbutyl}amine, has been prepared previously through the reaction of N,N′-bis(chloroacetyl)-2,4-pentanediamine with methylamine (Mikukami F. 1975). We have prepared the compound in a completely different way by following a similar procedure as that used for compound 1.

(2-pyridylmethyl){3-[(2-pyridylmethyl)amino]propyl}amine, 8, is a known compound but was prepared by a completely different procedure than that found in the literature. Instead of making this compound via the two step process of a Schiff base condensation of pyridine-2-carboxaldehyde with 1,3-propanediamine followed by a reduction reaction (Fischer H. R. et al 1984), we prepared it directly through a nucleophilic substitution of picolyl chloride with 1,3-propanediamine. This results in higher overall yields since we employ a one step process.

The preparation of the novel compound 9, methyl(3-[methyl(2-pyridylmethyl)amino]propyl)(2-pyridylmethyl)amine, was performed in a fashion similar to that used to synthesize 8. The product was of high purity and its analytical data matched the desired structure.

Compound 10, [2-(dimethylamino)ethyl](3-{[2-(dimethylamino)ethyl]methylamino}propyl)methylamin, was prepared by the literature procedure (Golub G. et al 1992.) and the synthesis resulted in a high yield of a pure product. Although the literature did not supply physical data for the compound, our results are consistent with the structure of the compound.

2-[3-2-aminoethylthio)propylthio]ethylamine, 11, is a known compound (Hay R. W. et al 1975) but was prepared by a novel procedure here. Nucleophilic substitution of 1,3-dimercaptopropane with 2-chloroethyamine resulted in formation of 11 that had physical properties similar to those reported.

The preparation of 1,4,8,11-tetraaza-1,4,8,11-tetramethylcyclotetradecane, 12, was performed in a manner similar to that found in the literature (Barefield K et al 1973). The analytical data for this compound matches that found previously.

Compound 13, 1,4,8,11-tetraaza-1,4,8,11-tetra(2-piperidylethyl)cyclotetradecane, was prepared from cyclam through a nucleophilic substitution in a fashion similar to the one we use to prepare compound 4. Many other derivatives of cyclam could be prepared using this type of reaction.

1,4,8,11-tetraaza-1,4,8,11-tetraethylcyclotetradecane, 15, is a known compound (Oberholzer M. R. et al 1995) but was prepared here by a modified procedure using similar reagents but with different reactions conditions and purification steps.

Compound 16 is a novel compound that incorporates phosphorous into the molecule in the place of the two nitrogens. This internal substitution is done via addition/reduction process and could be changed to include oxygen or other donors if desired.

Compound 17, 3-(3-(2-aminoethoxy)propoxy)propylamine, is a novel compound that incorporates oxygen into the molecule in place of two of the nitrogens of 2,3,2-tetramine. This internal substitution is done via Williamson-type chemistry starting with a di-alkoxide and a di-alkyl halide.

The preparation of the novel vanadium complexes 18, 20 and 22 occurs in straight-forward fashion by mixing a vanadium precursor with the appropriate starting material. The novel chromium complexes 19, 21, and 23 are prepared in similar fashion using a chromium precursor.

Compound 24, p-Phosphonomethyl)-DL-phenylalanine, is a known compound (Marseigne, L, et al 1988) that was prepared in six steps starting from p-cyanobenzylbromide. This compound was converted into its butylamine salt by treatment of 24 with an aqueous solution of butylamine followed by precipitation. Numerous other salts of this compound could be prepared, all of which would have substantially modified properties.

Compound 24 was used as one of the precursors for the preparation of 25, 2-amino-N-(2-{[3-(2-amino-3-4-phosphonomethylphenyl)propanolylamino]ethyl}amino)propyl]amino}ethyl-3-(4-phosphonomethylphenyl)propamide, by reacting Boc-protected 24 with 2,3,2-tetramine, 1, after activation of the carboxylic acid group. This novel compound 25 incorporates the tyrosine phosphate inhibitor group into the tetramine backbone. Compound 24 could be added to any number of the amines described here to form novel polyamine compounds.

The preparation of 2,2′ diamino (bis-N,N-pyridylmethyl)biphenyl, 26, has been described previously (Malachowski M. R. et al 1999). The novel compound 27, 2,2′-diamino(bis-N,N′-pyridylmethyl)-6,6-dimethylbiphenyl illustrates an example of incorporating additional substituents onto the biphenyl rings, in this case methyl groups in the 6,6′-positions. This will force the rings further out of plane. Compound 27 was made by an Ullman coupling of substituted benzenes followed by a two-step process involving catalytic hydrogenation and then reaction of the amine with 2-pyridinecarboxaldehyde and NaBH₄.

The new compound 28, 2,2′-diamino (bis-N,N-quinilylmethyl)biphenyl was prepared by the formation of the intermediate imine via a substitution-elimination pathway starting with 2,2′-diaminobiphenyl and 2quinoline carboxaldehyde. This reaction was followed by a reduction of the imine using NaBH₄. Compound 28 is a novel compound related to compound 26 where the pyridine rings are replaced with the bulkier quinoline rigs.

Compound 29, [(3,5-dimethylpyrazolyl)methyl][2-2-{[(3,5-dimethylpyrazolyl)methyl]amino}phenyl)phenyl]amine is prepared for the first time and incorporates pyrazole rings via a nucleophilic substitution pathway, using 2,2′-diaminobiphenyl and 3,5-dimethyl-N-hydroxymethylpyrazole as the stating materials. Compound 30, 2-{[(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol, is a known compound that is formed via the preparation of the Schiff-base followed by reduction with sodium borohydride (Goodwin k et al 1960).

It is also of value to generate polyamine compounds with less symmetry so the two rings of the biphenyls are substituted with different groups. Compound 31, 2-({[2-(2-{[2-hydroxyphenyl)methyl]amino}phenyl)phenyl]amino}methyl)phenol is a known compound that contains three nitrogens and one oxygen (Melby L. R et al 1975). Derivatives of 31 where the phenol ring is substituted with a CH₃ in the 4position led to the new compound 32, 4-methyl-2-{[(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol. This compound was formed by the reaction of N-2-pyridylmethyl)-2,2′-diamino biphenyl with the substituted salicylaldehyde.

Compound 33, 3-nitro-2-{[(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol was synthesized in similar fashion by treating the nitro-substituted salicylaldehyde with the same polyamine as used for 32 while 34, 4-chloro-2-{[(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol is prepared with the suitable chloro-substituted precursor compound. This addition-elimination-reduction sequence could be exploited for a large number of substituted salicylaldehydes.

Compound 35, 2, amino-3-(-(4-phosphonomethylphenyl)-N-(2-{-2-[benzylamino]phenyl)phenyl)propamide, incorporates components of the tyrosine phosphate inhibitor and the biphenyl rings to form the polyamine. 35 was prepared by reacting N-(2-pyridylmethyl)-2,2′diamino biphenyl with the Boc-protected amino acid molecule 24 followed by deprotection with acid. Numerous related polyamines that incorporate the biphenyl backbone can be prepared in this fashion.

Various metal complexes of the examples described above were prepared Compound 36 resulted from the reaction of MICl₂ with 2,2′diamino (bis-N,N′-quinilylmethyl)biphenyl (28) in a substitution reaction. Compound 37 incorporates iron into a complex with 34 via the reaction of FeCl₃ while 38 is formed by reacting VCl₂ with Compound 26. The gadolinium complex 39 was prepared via the reaction of 26 with GdCl₃. Compound 40 was prepared by the reaction of CrCl₃ with 30 resulting in the chromium complex Numerous other metals such as copper, cobalt, technetium and other transition metals reacting with compounds 1-17 and 24-35 should lead smoothly to novel metal complexes.

Compounds 1 to 40 correspond with FIGS. 1 to 40 and Examples 1 to 40.

The following examples are intended to illustrate but not to limit the number of compounds within the scope of the invention.

EXAMPLE 1

1,3bis-[(2′-aminoethyl)-amino]propane [FIG. 1]

A mixture of 15 g of 1,3-dibromopropane and 50 mL of absolute EtOH was added slowly to 25 g of 1,2 diaminoethane hydrate. The mixture immediately became warm. It was then heated to 500C for 1 hour, 20 g of KCl added and the heating continued for 30 minutes. The mixture was filtered from the KBr and distilled at reduced pressure. The residue formed two layers that were separated. The top layer was distilled and the product had a b.p. of 115-116° C., (1 mm). The compound was further purified by converting the free amine to its tetrahydrochloride salt by addition of 6M. HCl. The melting point of the salt was 278-283° C. It was converted back to its free amine by treatment with NH₄OH. Mass spectral analysis showed a m/e=160. ¹H NMR (CDCl₃): δ 1.26 (6H, s), 1.60 (2H, quin), 2.60 (4H, t), 2.71 (8H, t).

EXAMPLE 2

[12(methylethylamino)ethyl](3-[(methylamino)ethyl]amino)propyl)amine [FIG. 2]

A mixture of 0.37 g (0.0155 mol) of magnesium turnings, 5.0 g (0.031 mol) of 1,3-bis-[(2′-aminoethyl)-amino]propane, 50 mL of benzene and 3.76 g (0.047 mol) of acetyl chloride is heated under reflux for 2 h. The reaction mixture is cooled in an ice bath and the liquid portion is decanted into a separatory funnel. The residue in the flask is washed twice with 50 mL portions of ether, and the ethereal solution is poured over ice. The ether-water mixture is then added to the benzene solution in the separatory funnel and separated. The organic phase is washed once with 50 mL of 5% sodium bicarbonate and once with water and dried over CaCl₂. The solution is filtered and used without further purification.

A magnetically stirred mixture of 5.0 g (8.67 mmol) of the acetylated 2,3,2-tetramine prepared above and 2.0 g (80.7 mmol) of sodium hydride in 75 mL of N,N-dimethylformamide was heated at 60° C. under N₂ for 3 h. The resultant mixture was treated with 19.8 g (0.164 mol) of iodomethane and stirred at 50° C. After 24 h at 50° C., the reaction was quenched by the addition of 95% EtOR Volatiles were removed at reduced pressure and 50 mL of water was added to the residue. The product was extracted with three 50 mL portions of chloroform. The combined organic extracts were successively washed with water and NaCl, dried over anhydrous sodium sulfate, and concentrated to give 6.3 g of yellowish oil. The oil was purified by flash chromatography with 1:4 hexanes-ethyl acetate as the eluent to give acetylated [2-(methylethylamino)ethyl](3-{[2-(methylamino)ethyl]amino}propyl)amine as an oil.

A stirred solution of 3.0 g (4.54 mmol) of acetylated [2-(methylethylamino)ethyl](3-{[2-(methylamino)ethyl]amino)propyl)amine, 10.0 g (0.178 mol) of potassium hydroxide, 70 mL of methanol and 15 mL of water was heated under reflux for 24 h. The methanol was removed at reduced pressure and the product was extracted into 2×50 mL of ether. The combined extracts were washed with NaCl, dried over sodium sulfate and concentrated under vacuum. The crude mixture was purified by flash chromatography with 5:1 hexanes-ethyl acetate as the eluent. After evaporation of the solvents, 0.79 g (71%) of the product was obtained as a colorless oil. Mass spectral analysis showed a m/e=244. ¹H NMR (CDCl₃): δ1.03 (12H, d), 1.26 (6H, s), 1.60 (2H, quin), 2.60 (4H, t), 2.71 (8H, t), 3.23 (2H, m).

EXAMPLE 3

(2-piperidylethyl)-(3-[(2-piperidylethyl)amino]propyl}amine [FIG. 3]

To a mixture of 0.5 g (6.75 mmol) of 1,3-diaminopropane and 50 mL of absolute EtOH was added 1.62 g (40.5 mmol) of NaOH To this solution was added dropwise 2.48 g (13.45 mmol) of 1-(2-chloroethyl)piperidine in 50 mL of EtOH over 30 min. The solution was allowed to stir for 24 h The solvent was evaporated and the residue was extracted with 2×50 mL of CH₂Cl₂, dried over Na₂SO₄, and evaporated to dryness. The compound was purified by converting it to its hydrochloride salt by addition of HCl. The melting point of the salt was >300° C. It was converted back to its free amine by treatment with NH₄OH. The resultant oil (1.04 g, 52%) was analyzed. Mass spectral analysis showed a m/e=297 (M+1). ¹H NMR (CDCl₃): δ 1.40-1.82 (14H, m), 2.40-2.58 (14H, quin), 2.60-2.72 (10H, m).

EXAMPLE 4

(2-piperazinylethyl)-3-[(2piperazinylethyl)amino]propyl)amine [FIG. 4]

To a mixture of 0.5 g (6.75 mmol) of 1,3-diaminopropane and 50 mL of absolute EtOH was added 1.62 g (40.5 mmol) of NaOH. To this solution was added dropwise 2.48 g (13.45 mmol) of 1-2-chloroethyl)piperizine in 50 mL of EtOH over 30 min. The solution was allowed to stir for 24 h. The solvent was evaporated and the residue was extracted with 2×50 mL of CH₂Cl₂, dried over Na₂SO₄, and evaporated to dryness. The compound was purified by converting it to its hydrochloride salt by addition of HCl. The melting point of the salt was >300° C. It was converted back to its free amine by treatment with NH₄OH. The resultant oil (0.82 g, 41%) was analyzed. Mass spectral analysis showed a m/e=299 (M^+·+1). ¹H NMR (CDCl₃): δ1.40-1.82 (10H, m), 2.42-2.55 (14H, quin), 2.58-2.77 (10H, m).

EXAMPLE 5

(2-aminoethyl)(3-[(2-aminoethyl)methylaminopropyl}methylamine [FIG. 5]

To a solution of 1.0 g (0.0128 mol) of N,N-dimethyl-1,3-propanediamine in 50 mL of EtOH was added a solution of 2.96 g (25.6 mmol) of 2-chloroethylamine in 50 mL of EtOH dropwise over 40 min The solution was stirred at room temperature for 20 h. The solvent was evaporated and the residue was extracted with 2×50 mL of CH₂Cl₂, dried over Na₂SO₄, and evaporated to dryness. The resultant oil (1.52 g, 63%) was distilled (bp 145-148, 1 mm). Mass spectral analysis showed a m/e=189 (M^+·+1). ¹H NMR (CDCl₃): δ 1.20 (4H, s), 1.60 (2H, quin), 2.29 (6H, s) 2.57 (4H, t), 2.73 (8H, t).

EXAMPLE 6

[2-(bicyclo[3.3.1]non-3-ylamino)ethyl](3-{2-(bicyclo[3.3.1]non-3-ylamino)ethyl]amino}propyl)amine [FIG. 6]

A mixture of 0.06 mol of 1-bromoadamantane and 0.30 mol of acetylated 2,3,2-tetramine were heated in a stainless steel bomb at 215° C. for 6 h The product was poured into a mixture of 250 mL of 2 N HCl and 200 mL of ether. The aqueous layer was separated and made alkaline with 200 mL of 50% aqueous NaOHR The mixture was extracted with ether and the extract dried over K₂CO₃ and evaporated to give an oil (1.32 g, 33%). Mass spectral analysis showed a m/e=406. ¹H NMR (CDCl₃): δ 1.24-1.30 (4H, s), 1.50-2.12 (32H, m), 2.62 (4H, t), 2.75 (8H, t).

EXAMPLE 7

(2aminoethyl){3-[(2aminoethyl)amino]-1-methylbutyl}amine [FIG. 7]

A mixture of 2.34 g (10 mmol) of 2,4-dibromopentane and 50 mL of absolute EtOH was added slowly to 1.2 g (20 mmol) of 1,2-diaminoethane hydrate. The mixture immediately became warm. It was then heated to 50° C. for 1 hour, 10 g of KCl added and the heating continued for 30 minutes. The mixture was filtered from the KBr and distilled at reduced pressure. The compound was purified by converting it to its hydrochloride salt by addition of HCl. The melting point of the salt was >300° C. It was converted back to its free amine by treatment with NH₄OH. Mass spectral analysis of the oil ((1.28 g, 68%) showed a m/e=188. ¹H NMR (CDCl₃): δ 1.12 (6H, d), 1.30-1.37 (6H, s), 1.60 (2H, t), 2.60 (2H, m), 2.74 (8H, t).

EXAMPLE 8

(2-pyridylmethyl){3-[(2pyridylmethyl)amino]propyl}amine [FIG. 8]

To a solution of 1.0 g (0.0135 mol) of 1,3-diaminopropane in 50 mL of EtOH was added a solution of 4.43 g (27.0 mmol) of 2-chloromethylpyridine in 25 mL of water. 10% NaOH was added until the pH reached 9. The solution was stirred at room temperature and NaOH was added to keep the pH at 8-9 over 3 days. The solvent was evaporated and the residue was extracted with 3×30 mL of CH₂Cl₂, dried over Na₂SO₄, and evaporated to dryness. The resultant oil (2.63 g, 76%) was analyzed. Mass spectral analysis showed a m/e=257 (M^+·+1). ¹H NMR (CDCl₃): δ 1.60 (2H, quin), 2.62 (4H, t), 4.06 (4H, s), 7.15-7.80 (6H, m), 8.44-8.63 (2H, d).

EXAMPLE 9

methyl(3[methyl(2-pyridylmethyl)amino]propyl)(2-pyridylmethyl)amine [FIG. 9]

To a solution of 1.0 g (0.0128 mol) of N,N-dimethyl-1,3-propanediamine in 50 mL of EtOH was added a solution of 4.19 g (25.6 mmol) of 2-chloromethylpyridine in 25 mL of water. 10% NaOH was added until the pH reached 9. The solution was stirred at room temperature and NaOH was added to keep the pH at 8-9 over 3 days. The solvent was evaporated and the residue was extracted with 3×30 mL of CH₂Cl₂, dried over Na₂SO₄, and evaporated to dryness. The resultant oil (2.69 g, 74%) was analyzed Mass spectral analysis showed a m/e=285 (M^+·+1). ¹H NMR (CDCl₃): δ 1.55 (2H, quin), 2.30 (6H, s), 2.58 (4H, t), 3.75 (4H, s), 7.07-7.85 (6H, m), (2H, d).

EXAMPLE 10

[2-(dimethylamino)ethyl](3-{[2-(dimethylamino)ethyl]methylamino}propyl)methylamine [FIG. 10]

A solution of 1.0 g (6.23 mmol) of 2,3,2-tetramine, 10 mL of formic acid, 10 mL of 37% formaldehyde and 1 mL of water was refluxed for 20 h The solvent was evaporated, the solution was made basic with 3 M NaOH, and was extracted with 3×30 mL of CH₂Cl₂, dried over Na₂SO₄, and evaporated to dryness. The resultant oil (0.88 g, 58%) was analyzed. Mass spectral analysis showed a m/e=244 (M^+·+1). ¹H NMR (CDCl₃): δ 1.62 (2H, quin), 2.24-2.30 (18H, s), 2.60 (4H, t), 2.71-2.75 (8H, t).

EXAMPLE 11

2-3-(2-aminoethylthio)propylthio]ethylamine [FIG. 11

To a solution of 1.0 g (0.0128 mol) of 1,3-dimercaptopropane in 50 mL of EtOH was added a solution of 1.48 g of NaOH in 10 mL of water. To the solution was added 214 g (18.48 mmol) of 2-chloroethylamine in 25 mL of EtOH. The solution was refluxed for 8 h. The solvent was evaporated and the residue was extracted with 3×25 mL of CH₂Cl₂, dried over Na₂SO₄, and evaporated to dryness. The resultant oil was distilled at 165-173 (1 mm) to give 1.81 g, 73%. Mass spectral analysis showed a m/e=194. ¹H NMR (CDCl₃): δ 1.48 (4H, s), 2.34-2.86 (14H, m).

EXAMPLE 12

1,4,8,11-tetraaza-1,4,8,11-tetramethylcyclotetradecane [FIG. 12]

A solution consisting of 1.0 g (0.005 mol) of cyclam, 5.3 mL of formic acid, 4.5 mL of 37% formaldehyde and 1 mL of water was refluxed for 18 h. The reaction mixture was transferred with 6 mL of water to a beaker and cooled to 5° C. in an ice bath While stirring, a concenrated solution of NaOH was slowly added to pH>12, The temperature was kept below 25° C. during the addition and then extracted with 3×30 mL of CH₂Cl₂., dried over Na₂SO₄, and evaporated to dryness. The resultant oil (0.98 g, 71%) was analyzed Mass spectral analysis showed a m/e=256. ¹H NMR (CDCl₃): δ 1.68 (4H, quin), 2.22 (12H, s), 2.64 (8H, t), 2.75 (8H, t).

EXAMPLE 13

1,4,8,11-tetraaza-1,4,8,11-tetra(2-piperidylethyl)cyclotetradecane FIG. [13]

To a solution of 0.5 g (2.5 mmol) of cyclam in 25 mL of CH₂Cl₂ was added a solution of 0.8 g of NaOH in 25 mL of water. A solution of 1.83 g (9.98 mmol) of 1-(2-chloroethyl)piperidine in 25 mL of CH₂Cl₂ was added dropwise at room temperature. The stirring was continued for 24 h. The solvent was evaporated and the residue was extracted with 3×50 mL of CH₂Cl₂, dried over Na₂SO₄, and evaporated to dryness. The resultant oil (0.725 g, 45%) was analyzed Mass spectral analysis showed a m/e=646 (W-+1). ¹H NMR (CDCl₃): δ 1.28 (8H, q), 1.46-1.72 (24H, m), 1.72 (4H, m), 2.42-2.80 (24H, m), 2.64 (8H, t), 2.75 (8H, t).

EXAMPLE 14

1,4,8,11-tetraaza-1,4,8,11-tetrabicyclo[3.3.1]non-3-ylcyclotetradecane [FIG. 14]

To 0.5 g (2.5 mmol) of cyclam in 50 mL of EtOH was added 2.15 g (10.0 mmol) of 1-bromoadamantane in 50 mL of EtOH dropwise over 30 min The solution was heated to reflux and heated for 20 h. The solution was evaporated under reduced pressure, extracted with 3×35 mL of CH₂Cl₂., dried over Na₂SO₄, and evaporated to dryness. The resultant oil (0.53 g, 31%) was analyzed. Mass spectral analysis showed a m/e=690 (M+1). ¹H NMR (CDCl₃): δ 1.24-1.58 (56H, m), 1.66 (4H, quin), 2.62 (8H, t), 2.70 (8H, t).

EXAMPLE 15

1,4,8,11-tetraaza-1,4,8,11-tetraethylcyclotetradecane [FIG. 15]

To a stirred solution of 1.0 g (5.0 mmol) of cyclam in 50 mL of DMF was added 4.0 g (0.1 mol) of NaH in small portions. The solution was heated under nitrogen at 60° C. for 3 h. 3.12 g (20 mmol) of iodoethane was added in one portion. The solution was heated at 60° C. for 18 h. The reaction was quenched with 95% EtOH, extracted with 3×35 mL of CH₂Cl₂., dried over Na₂SO₄, and evaporated to dryness. The resultant oil was purified by flash chromatography using ethyl acetate/MeOH. Mass spectral analysis of the oil (0.72 g, 46%) showed a m/e=312. ¹H NMR (CDCl₃): δ 1.38 (1214, t), 2.16 (8H, q), 3.38 (4H, quin), 3.54 (8H, t), 3.80 (8H, t).

EXAMPLE 16

N,N′-(2′-dimethylphosphinoethyl)propylenediamine [FIG. 16]

Propylenediamine (4.0 g) was dissolved in 200 mL of ethanol. To the solution was added 9.4 g of dimethylvinylphosphine sulfide and the mixture was heated at reflux for 72 h. The solvent was evaporated under reduced pressure and the residue dissolved in 400 mL of chloroform and washed with 50 mL of 2 M NaOH and dried over MgSO₄. The solvent was removed under reduced pressure to give an oil that was crystallized from ethyl acetate to give 6.8 g (51%) of the pure product. To a suspension of LiAlH4 (1.2 g) in 125 mL of dry dioxane was added N,N′-(2′-dimethylphosphinothioethyl)-propylenediamine (prepared as above). The mixture was refluxed for 36 h. The mixture was cooled, dioxane/water added, 3 mL of 2 M NaOH added and then the solution was filtered to give the pure phosphine. ¹H NMR (CDCl₃): δ 1.64(2H, quin), 2.10 (12H, s), 2.57 (4H, t), 2.55-2.80 (8H, m).

EXAMPLE 17

3-(3-(2-aminoethoxy)propoxy)propylamine [FIG. 17]

Sodium 0.20 g, (8.6 mmol) was added in small portions to 50 mL of ethanol. After evolution of hydrogen ceased, 0.33 g (4.3 mmol) of 1,3 propanediol was added and stirred for 1 h 2-chloroethylamine (1.0 g, 8.6 mmol) in 50 mL of ethanol was added dropwise over 30 min. The solution was refluxed for 8 h and the solvent was evaporated. The resultant oil was dissolved in 50 mL of water and extracted with 2×50 mL of CH₂Cl₂ dried over Na₂SO₄, filtered and evaporated. The oil was flash chromatographed using 1:1 ethyl acetate/hexane to give 0.32 g (46%) of 3-3-(2-aminoethoxy)propoxy)propylamine. ¹H NMR (CDCl₃): δ 1.32(4H, s), 1.68 (2H, q), 2.71 (2H, t), 2.96 (8H, t). MS m/z 162 (calcd 162).

EXAMPLE 18

Vanadyl 2,3,2-Tetramine [FIG. 18]

To 1.0 g (0.624 mol) of 2,3,2 tete in 20 ml of EtOH was added 0.073 g (0.0624 mol) of vanadylacetylacetonate in 20 ml of EtOH. The solution was refluxed for 30 min and cooled to room temperature. Overnight a red-brown solid precipitated. The complex is formulated as being [VO(2,3,2-tetramine)acac].

EXAMPLE 19

Chromium 2,3,2-Tetramine [FIG. 19]

To 1.0 g (0.0624 mol) of 2,3,2-tetramine in 20 ml of EtOH was added 0.245 g (0.0624 mol) of chromium (E) nitrate in 20 ml. Of EtOH. The solution was refluxed for 30 min and cooled to room temperature. Overnight a solid precipitated. The complex is formulated as being [Cr(2,3,2-tetraamine)(NO₃)₂]NO₃.

EXAMPLE 20

Vanadyl ((2-piperidylethyl)-{3-[(2-piperidylethyl)amino]propyl}amine)(Cl)₂ [FIG. 20]

To 200 mg (0.67 mmol) of 2,3,2-pip in 25 mL of methanol was added a solution of 82 mg (0.67 mmol) of V(II)Cl₂ in 15 mL of methanol. The solution was heated for 30 min and cooled to room temperature. Crystals of Vanadyl ((2-piperidylethyl)-{3-[(2-piperidylethyl)amino]propyl}amine)(Cl)₂ formed overnight which were collected and dried. Anal. Calcd for VC₁₅Cl₂H₃₄N₆: C, 42.86; H. 8.17; N, 19.98. Found: C, 42.33; H. 8.24; N, 20.03.

EXAMPLE 21

Chromium ((2-piperidylethyl)-{3-[(2-piperidylethyl)amino]propyl}amine)(Cl)₂]Cl [FIG. 21]

To 200 mg (0.67 mmol) of 2,3,2-pip in 25 mL of methanol was added a solution of 178 mg (0.67 mmol) of Cr(III)Cl₃ in 25 mL of methanol. The solution was heated for 30 min, cooled to room temperature and the solvent was evaporated to 20 mL. Crystals of [Chromium ((2-piperidylethyl)-{3-[(2-piperidylethyl)amino]propyl}amine)(Cl)₂]Cl formed overnight which were collected and dried. Anal. Calcd for CrCl₅C₁₃H₃₄N₆: C, 39.43; H, 7.52; N, 18.39. Found: C, 39.05; H, 7.19; N, 18.54.

EXAMPLE 22

Vanadyl (1,4,8,11-tetraaza-1,4,8,11-tetrabicyclo[3.3.1]non-3-ylcyclotetradecane)(Cl)₂ [FIG. 22]

To 300 mg (0.41 mmol) of cyclam-ad in 25 mL of methanol was added a solution of 50 mg (0.41 mmol) of V(II)Cl₂ in 10 mL of methanol. The solution was heated for 30 min, cooled to room temperature and the solvent evaporated to 10 mL. Crystals of Vanadyl (1,4,8,11-tetraaza-1,4,8,11-tetrabicyclo[3.3.1]non-3-ylcyclotetradecane)(Cl)₂ formed in 72 h which were collected and dried. Anal. Calcd for VC₅₀Cl₂H₈₀N₄: C, 69.24; H, 9.32; N, 6.45. Found: C, 69.01; Et 9.45; N, 6.88.

EXAMPLE 23

Chromium (1,4,8,11-tetraaza-1,4,8,11-tetrabicyclo[3.3.1]non-3-ylcyclotetradecane)(Cl)₂]Cl [FIG. 23]

To 300 mg (0.41 mmol) of cyclam-ad in 25 mL of methanol was added a solution of 108 mg (0.41 mmol) of Cr(III)Cl₃ in 20 mL of methanol. The solution was heated for 30 min, cooled to room temperature and the solvent evaporated to 10 mL. Crystals of Chromium (1,4,8,11-tetraaza-1,4,8,11-tetrabicyclo[3.3.1]non-3-ylcyclotetradecane)(Cl)₂]Cl formed overnight which were collected and dried. Anal. Calcd for CrC₅₀Cl₃H₈₀N₄: C, 67.04; H. 9.02; N, 6.25. Found: C, 67.11; H. 8.89; N, 6.41.

EXAMPLE 24

p-(Phosphonomethyl)Diphenylalanine-Butylamine Salt [FIG. 24]

A solution of Na (0.26 g, 0.011 mol), diethyl acetamidomalonate (2.17 g, 0.01 mol), and p-cyanobenzyl bromide (1) (1.96 g, 0.01 mol) in 25 mL of ethanol was refluxed and stirred for 17 h at 110° C. After cooling and addition of water (50 mL), the crystalline material was collected by filtration and washed twice with water, to yield 2.89 g (87%) of the white solid Diethyl (4-Cyanobenzyl)acetamidomalonate. ¹H NMR (DMSOd) δ 1.12 (t, 6H), 1.93 (s, 3H), 3.42 (s, 2H), 4.14 (q, 4H,), 7.16-7.80 (2 d, 4H), 8.15 (s, 1H).

Diethyl (4-Cyanobenzyl)acetamidomalonate (996 mg, 3 mmol) was hydrogenated at atmospheric pressure and room temperature for 22 h in ethanol (25 mL) and concentrated HCl (1.5 mL) with Pd/C 10% as catalyst (200 mg). After filtration, the solution was taken to dryness. Water (60 mL) was added to the residue and unreacted material was removed by filtration. The filtrate was again concentrated to dryness, giving 956 mg (85%) of the white solid Diethyl [4-(Aminomethyl)benzyl]acetamidomalonate. ¹H NMR (DMSO d) δ 1.12 (t, 6H), 1.92 (s, 3H), 3.40 (s, 2H), 3.88 (s, 2H), 4.11 (q, 4H), 7.03-7.38 (2 d, 4H), 8.21 (s, 3H).

A solution of Diethyl [4-Aminomethyl)benzyl]acetamidomalonate (2.06 g, 5.5 mmol), NaNO₂ (535 mg), and water (100 mL) was heated for 3 h at 110° C., cooled, and extracted with ethyl acetate. The extract was washed with 1 M HCl, water, 5% NaHCO₃, water and brine, dried over Na₂SO₄, filtrated, and taken to dryness, giving a white crystallized solid Diethyl [4-(Hydroxymethyl)benzyl]acetamidomalonate. 1.55 g (83%); ¹HNMR (DMSO-d₆) δ 1.10 (t, 6H), 1.90 (s, 3H), 3.38 (s, 2H), 4.12 (q, 4H), 4.48 (d, 2H), 5.04 (t, 1H), 6.82-7.10 (2 d, 4H), 7.92 (s, 1H).

A solution of Diethyl [4-(Hydroxymethyl)benzyl]acetamidomalonate (210 mg, 0.6 mmol) and thionyl chloride (1.4 mL, 30 equiv) in dichloromethane (15 mL) was refluxed for 18 h and concentrated to dryness. The residue was washed twice with diethyl ether, to give the white solid Diethyl [4-(Chloromethyl)benzyl]acetamidomalonate. 152 mg (68%); ¹H NMR (DMSO-d₄) 1.10 (t, 6H), 1.90 (s, 3H), 3.40 (s, 2H), 4.17 (q, 4H), 4.69 (s, 2H), 6.90-7.38 (2 d, 4H), 8.09 (s, 1H).

Diethyl [4-(Chloromethyl)benzyl]acetamidomalonate (50 mg, 0.14 mmol) was dissolved in triethyl phosphite (4 mL) and refluxed for 22 h. After removal of triethyl phosphite, the oily residue was purified by flash chromatography on silica gel with CH₂Cl₂—CH₃OH (90:10) as eluent, to yield 45.6 mg (71%) of the white solid Diethyl [4-[(Diethoxyphosphinyl)methyl]benzyl]acetamidomalonate. ¹H NMR (DMSO-d₆) δ 1.11 (t, 12H) 1.88 (s, 3H), 3.12 and 3.15 (s, 2H), 3.38 (s, 2H), 3.92 (m, 4H), 4.09 (q, 4H), 6.88-7.18 (d, 4H), 7.92 (s, 1H).

A solution of Diethyl [4-[(Diethoxyphosphinyl)methyl]benzyl]acetamidomalonate (55 mg, 0.06 mmol), 1 N NaOH (0.5 mL, 4 equiv) in water (2 mL), and methanol (2 mL) was stirred for 3 h at room temperature. After addition of 8 mL of water and 5 mL of concentrated HCl, the reaction mixture was refluxed for 4 h (110° C.), cooled, and, after addition of 20 mL of water, adjusted to pH 4 with 10% NaOH. After lyophilization and purification by chromatography on silica gel with 2-propanol-NH₄OH (28%) (60:40) as eluent, the white product (14.2 mg, 40% yield) p-(Phosphonomethyl)-DL-phenylalanine was obtained: ¹H NMR (D₂O) (TMS as external reference) δ 2.70 and 2.83 (s, 2H,), 2.88 and 3.12 (dd, 2H), 3.74 (m, 1H), 7.10 and 7.22 (d, 4H); mass spectrum (FAB), m/e (MH)⁺ calcd 296, found 296. The compound was converted into its butylamine salt by treatment with butylamine followed by precipitation from an aqueous solution.

EXAMPLE 25

2-amino-N-(2-{[3-(2-[2-amino-3-(4-phosphonomethylphenyl) propanolylaminolethyl)amino)propyl]amino)ethyl)-3-(4-phosphonomethylphenyl)propanamide [FIG. 25]

To 5 mL of dioxane was added 2.0 g (7.7 mmol) of p-(phosphonomethyl)-DL-phenylalanine, 0.82 g (8.1 mmol) of triethylamine and 1.68 g (7.7 mmol) of di-tert-butyl dicarbonate. The solution was stirred at room temperature for 3 hours. The solution was evaporated at reduced pressure to dryness. The resultant oil was purified by column chromatography using methanol/chloroform to yield 2.1 g (77%) of the Boc-p-(phosphonomethyl)-DL-phenylalanine.

To a solution of 0.5 g (3.1 mmol) of 2,3,2-tetra ine in 10 mL of DMF was added 2.24 g (6.2 mmol) of Boc-p-phosphonomethyl)-DL-phenylalanine at 0° C. under an atmosphere of nitrogen. To this solution was added a solution of DPPA (1 mL, 3.2 mmol) in 10 mL of DMF and 0.35 g (3.2 mmol) of powered NaHCO₃. The solution was vigorously stirred for 24 hours at 0° C. The solution was diluted with ethyl acetate, washed with 1 N HCl, followed by saturated NaHCO₃. The solution was dried over MgSO₄, filtered, and evaporated under reduced pressure. The oil was purified by flash chromatography to give 1.2 g (46%) of Boc-2-amino-N-(2-{[3-(2-[2-amino-3-4-phosphonomethylphenyl) propanolylamino]ethyl)amino)propyl]amino}ethyl)-3-(4-phosphonomethylphenyl)propanamide as a colorless oil.

A solution of Boc-2-amino-N-2-([3-2-[2-amino-3-(4-phosphonomethylphenyl) propanolylamino]ethyl]amino)propyl]amino}ethyl)-3-(4-phosphonomethylphenyl)propanamide (0.5 g, 0.59 mmol) in 10 mL of methylene chloride and 2 mL of trifluoroacetic acid was stirred at room temperature for 30 min. The solvent was evaporated at reduced pressure. 2-amino-N-(2-{[3-(2-[2-amino-3-(4-phosphonomethylphenyl) propanolylamino]ethyl}amino)propyl]amino}ethyl)-3-(4-phosphonomethylphenyl)propanamide was isolated as the trifluroacetic acid salt which was treated with ammonia to give 0.20 g (52%) 2-amino-N-(2-{[3-(2-[2-amino-3-(4-phosphonomethylphenyl) propanolylamino]ethyl}aminopropyl]amino}ethyl)-3-4-phosphonomethylphenyl)propanamide. ¹H NMR (D₂O) (TMS as external reference) δ 1.32 (8H, s), 1.62 (2H, quin), 2.57 (4H, t), 2.66 (8H, t), 2.75 (4H, s), 2.82 and 3.10 (4H, dd), 3.76 (2H, m), 7.12-7.28 (8H, m).

EXAMPLE 26

2,2′-diamino (bis-NN′-pyridylmethyl)biphenyl [FIG. 26]

To a solution of 1.0 g (5.43 mmol) of 2,2′-diaminobiphenyl in 50 mL of EtOH is added a solution of 3.56 g (21.7 mmol) of 2-picolylchloride hydrochloride in 15 mL of H₂O. A 10% solution of NaOH was added dropwise to the stirring solution until the pH reaches 8-9. A color change from a light yellow to a red-orange is observed at pH 8. The solution is stirred at room temperature and NaOH is added over 5 days to maintain the pH at 8. During this time, precipitation of an off-white solid occurs. The reaction is complete when the pH no longer drops below 8. The precipitate is collected by filtration and recrystallized from EtOH resulting in 1.51 g (75.9% yield) of white crystals of 2,2′-(bis-NN′-pyridylmethyl)biphenyl, mp 135-136° C., lit. mp 1370C.^8b Mass spectrum (AB MS), m/z (relative intensity); 367 (100), 274 (35), 195 (23), 180 (29). HRMS (FAB, MNBA) calcd for C₂₄H₂₃N₄ ([M+H]⁺): 366.1922, found 366.1923. ¹H NMR (CDCl₃): 01.62 (2K broad s), 4.48 (4H, s), 6.61-6.83 (8H, m), 7.04-8.50 (6H, m), 8.53 (2H, d). MS m/z 367 (calcd 367). Anal. Calcd for C₂₄H₂₂N₄: C, 78.65; It 6.06; N, 15.28. Found: C, 79.00; H 5.84; N, 15.62.

EXAMPLE 27

2,2′-diamino(bis-N,N′-pyridylmethyl)-6,6′-dimethylbiphenyl [FIG. 27]

To 6.0 g (8.2 mmol) of 6,6′-dimethyl-2,2′-dinitrobiphenyl in 75 mL of EtOH was added 1.0 g of palladium on carbon. The solution was hydrogenated on a Parr system for 4 hours at 60 psi. The catalyst was filtered and the solution was reduced to an oil under reduced pressure. The oil was crystallized from EtOH to yield 5.6 g (75.0%) of the off-white product (mp 66-67° C.) 2,2′-diamino-6,6′-dimethylbiphenyl.

To a refluxing solution of 1.5 g (7.06 mmol) of 2,2′-diamino-6,6′-dimethylbiphenyl in 40 mL of EtOH was added 1.48 g (14.12 mmol) of 2-pyridinecarboxaldehyde in 25 mL of EtOH. The solution was refluxed for 8 h and the solution turns yellow. The solution was cooled and 1.1 g of NaBH₄ was added in one portion. The solution was stirred for 2 days and the solution turned colorless. The solution was evaporated at reduced pressure, the residue was dissolved in water and extracted with 2×50 mL of ether. The ether was evaporated and the residue was crystallized from ethyl acetate/hexane to give white crystals of 2,2′-diamino(bis-N,N′-pyridylmethyl)-6,6′-dimethylbiphenyl. H NMR (CDCl₃): □2.21 (6H, s), 4.23 (4H, s), 7.02-8.13 (14H, m).

EXAMPLE 28

2,2′-diamino (bis-N,N′-quinilylmethyl)biphenyl [FIG. 28]

To 1.0 g (5.43 mmol) of 2,2′-diaminobiphenyl in 50 mL of ethanol was added 1.71 g (10.9 mmol) of 2-quinolinecarboxaldehyde. The solution was refluxed for 30 min, cooled to room temperature and the cooled to 0° C. Crystals of 1-aza-1-(2-(2-(1-aza-2-(3-isoquinolyl)vinyl)phenyl)phenyl)-2-(3-isoquinolyl)ethene were collected, mp 138-140° C.

To 1.0 g (3.62 mmol) of 1-aza-1-(2-(2-(1-aza-2-(3-isoquinolyl)vinyl)phenyl)phenyl)-2-3-isoquinolyl)ethene in 50 mL of ethanol was added 0.2 g of NaBH₄. The solution was refluxed for 30 min and then stirred at room temperature for 22 h. The solution was treated with concentrated HCl until acidic, extracted with 2×25 mL of CH₂Cl₂, dried over NaSO₄ and evaporated under reduced pressure. The resultant oil was crystallized from ethanol to yield 1.36 g (64%) of 2,2′-diamino(bis-NN′-quinilylmethyl)biphenyl, mp 156-158° C. ¹H NMR (CDCl₃): □4.60 (4H, d), 5.25 (2H, t), 7.10-8.15 (20H, m).

EXAMPLE 29

[(3,5-dimethylpyrazolyl)methyl][2-(2-([(3,5 dimethylpyrazolyl)methyl]amino)phenyl)phenyl]amine [FIG. 29]

To 1.49 g (8.09 mmol) of 2,2′-diaminobiphenyl in 100 mL of acetonitrile was added 2.0 g (16.2 mmol) of N-hydroxymethyl(3, 5 diethyl)pyrazole. The solution was stirred at room temperature for 3 days. The solution was dried over MgSO₄, filtered and evaporated to dryness under reduced pressure. The resultant oil was crystallized from ethyl acetate to give [(3,5dimethylpyrazolyl)methyl][2-(2-{[(3,5-dimethylpyrazolyl)methyl]amino}phenyl)phenyl]amine. ¹H NMR (CDCl₃): □2.18 (6H, s), 2.26 (6E, s), 3.81 (2H, broad s), 4.52 (4H, s), 5.30 (2H, s), 6.63-8.13 (8H, m).

EXAMPLE 30

2-{[(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol [FIG. 30]

To 1.0 g (5.68 mmol) of 2,2′-diaminobiphenyl in 20 mL of ethanol was added 1.38 g (11.3 mmol) of salicylaldehyde. The solution was refluxed for 30 min and cooled in an ice bath. Yellow crystals (1.76 g) of 2-(2-aza-2-(2-(1-aza-2-(2-hydroxyphenyl)vinyl)phenyl)phenyl)vinyl)phenol mp 145-146° C.

To 1.0 g (2.55 mmol) of 2-(2-aza-2-(2-(1-aza-2-(2-hydroxyphenyl)vinyl)phenyl) phenyl)vinyl)phenol in 25 mL of ethanol was added 0.3 g (7.93 mmol) of NaBH. The solution was refluxed for 30 min and stirred at room temperature for 24 h. The solution was treated with concentrated HCl until acidic, extracted with 2×25 mL of CH₂Cl₂, dried over NaSO₄ and evaporated under reduced pressure. The resultant oil was cystallizd from ethyl acetate/hexane to yield 0.72 g (73%) of 2-({[2-2-{[2-hydroxyphenyl)methyl]amino}phenyl)phenyl]amino}methyl)phenol. ¹H NMR (CDCl₃): □1.72 (2H, broad s), 4.25 (4H, s), 7.12-7.70 (16H, m).

EXAMPLE 31

2-({[2-(2{[-hydroxyphenyl)methyl]amino}phenyl)phenyl]amino}methyl)phenol [FIG. 31]

To 1.00 g (3.63 mmol) of N-(2-pyridylmethyl)-2,2′-diaminobiphenyl in 25 mL of ethanol was added 0.48 g (3.63 mmol) of salicylaldehyde. The solution was refluxed for 30 min and cooled to room temperature. The solution was evaporated to 10 mL and cooled at °0. Yellow crystals were collected by suction filtration to yield 0.90 g (72%) of 2-(2-aza-2-(2-(2-pyridylmethyl)amino)phenylphenyl)vinyl)phenol, mp 110-112° C.

To 2.0 g (7.26 mmol) of 2-(2-aza-2-(2-(2-pyridylmethyl)amino)phenyl)phenyl) vinyl)phenol in 50 mL of ethanol was added 0.3 g of NaBH. The solution was sired at room temperature for 24 h. The solution was treated with concentrated HCl until acidic, extracted with 2×25 mL of CH₂Cl₂, dried over NaSO₄ and evaporated under reduced pressure. The resultant oil was crystallized from methanol to yield 1.36 g (64%) of 2-{[(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol. mp 154-156° C. H NR (CDCl₃): 01.60 (2H, broad s), 4.42 (4H, s), 6.81-8.23 (16H, m). MS m/z 426 (calcd 426).

EXAMPLE 32

4-methyl-2-{[(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol [FIG. 32]

To 0.60 g (2.18 mmol) of N-(2-pyridylmethyl)-2,2′-diaminobiphenyl in 25 mL of ethanol was added 0.30 g (2.18 mmol) of 2-hydroxy-5-methylbenzaldehyde. The solution was refluxed for 30 min and cooled to room temperature. The solution was evaporated to 10 mL and cooled at °0. Yellow crystals were collected by suction filtration to yield 0.90 g (72%) of 2-(2-aza-2-(2-(2-pyridylmethyl)amino)phenyl)phenyl)vinyl)-4-methylphenol, mp 158-160° C.

To 2.0 g (7.26 mmol) of 2-2-aza-2-(2-(2-pyridylmethyl)amino)phenyl)phenyl)vinyl)-4-methylphenol in 50 mL of ethanol was added 0.3 g of NaBH₄. The solution was stirred at room temperature for 24 h. The solution was treated with concentrated HCl until acidic, extracted with 2×25 mL of CH₂Cl₂, dried over NaSO₄ and evaporated under reduced pressure. The resultant oil was crystallized from methanol to yield 1.36 g (64%) of 4-methyl-2-{[(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol. mp 135-137° C. ¹H NMR (CDCl₃): □1.68 (1H, broad s), 2.03 (3H, s), 4.40 (4H, s), 6.82-8.20 (15H, m).

EXAMPLE 33

3-nitro-2-{[(2-{2-[(2-pyridylmethylamino]phenyl}-phenylamino]methyl}phenol [FIG. 33]

To 0.60 g (2.18 mmol) of N-(2-pyridylmethyl)-2,2′-diaminobiphenyl in 10 mL of ethanol was added 0.36 g (2.18 mmol) of 2-hydroxy-6-nitrobenzaldehyde. The solution was refluxed for 30 min and cooled to room temperature. Yellow crystals were collected by suction filtration to yield 0.36 g (41%) of 2-(2-aza-2-(2-(2-pyridylmethyl)amino)phenyl)phenyl)vinyl)-5-nitrophenol, mp 114-115° C.

To 0.35 g (1.59 mmol) of 2-(2-aza-2-(2-(2-pyridylmethyl)amino)phenyl)phenyl)vinyl)-5-nitrophenol in 50 mL of ethanol was added 0.72 g (19.0 mmol) of NaBH₄. The solution was stirred at room temperature for 24 h. The solution was treated with concentrated HCl until acidic, extracted with 2×25 mL of CH₂Cl₂, dried over NaSO₄ and evaporated under reduced pressure. The resultant oil was crystallized from methanol to yield 0.24 g (61%) of 3-nitro-2-{[(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol. mp 178-180° C. ¹H NMR (CDCl₃): □1.53 (1H, broad s), 4.16 (4H, s), 6.92-8.01 (15H, m).

EXAMPLE 34

4-chloro-2-{[(2-{2-[(2pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol [FIG. 34]

To 0.60 g (2.18 mmol) of N-(2-pyridylmethyl)-2,2′-diaminobiphenyl in 10 mL of ethanol was added 0.34 g (2.18 mmol) of 5-chlorosalicylaldehyde. The solution was refluxed for 30 min and cooled to room temperate. Yellow crystals were collected by suction filtration to yield 1.06 g (77%) of 2-(2-aza-2-(2-(2-pyridylmethyl)amino)phenyl)phenyl)vinyl)₄chlorophenol, mp 115-116° C.

To 0.35 g (0.91 mmol) of 242-aza-242-(2-pyridylmethyl)amino)phenyl)phenyl)vinyl)₄-chlorophenol in 50 mL of ethanol was added 0.19 g of NaBH₄. The solution was stirred at room temperature for 24 h. The solution was treated with concentrated HCl until acidic, extracted with 2×25 mL of CH₂Cl₂, dried over NaSO₄ and evaporated under reduced pressure. The resultant oil was crystallized from ethyl acetate to yield 0.20 g (57%) of 4-chloro-2-{([(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol mp 172-174° C. ¹H NMR (CDCl₃): □1.62 (1H, broad s), 4.52 (4H, s), 7.02-8.31 (15H, m).

EXAMPLE 35

2-amino-3-(-(4-phosphonomethylphenyl)-N-(2-{2-[benzylamino]phenyl}phenyl)propanamide [FIG. 35]

To 5 mL of dioxane was added 2.0 g (7.7 mmol) of p-(phosphonomethyl)-DL-phenylalanine, 0.82 g (8.1 mmol) of triethylamine and 1.68 g (7.7 mmol) of di-tert-butyl dicarbonate. The solution was stirred at room temperature for 3 hours. The solution was evaporated at reduced pressure to dryness. The resultant oil was purified by column chromatography using methanol/chloroform to yield 2.1 g (77%) of the Boc-p-(phosphonomethyl)-DL-phenylalanine.

To a solution of 0.77 g (2.78 mmol) of N-(2-pyridylmethyl)-2,2′-diaminobiphenyl in 10 mL of DMF was added 1.0 g (2.78 mmol) of Boc-(phosphonomethyl)-DL-phenylalanine at 0° C. under an atmosphere of nitrogen. To this solution was added a solution of DPPA (1 mL, 2.88 mmol) in 10 mL of DMF and 0.3 g (2.88 mmol) of powered NaHCO₃. The solution was vigorously stirred for 30 hours at 0° C. The solution was diluted with ethyl acetate, washed with 1 N HCl, followed by saturated NaHCO₃. The solution was dried over MgSO₄, filtered, and evaporated under reduced pressure. The oil was purified by flash chromatography to give 1.0 g (62%) of Boc-2-amino-3-(−4-phosphonomethylphenyl)-N-2-{2-[benzylamino]phenyl}phenyl) propanamide as a colorless oil.

A solution of Boc-2-amino-3-(-(4-phosphonomethylphenyl)-N-(2-{2-[benzylamino]phenyl}phenyl) propanamide (0.5 g, 0.81 mmol) in 10 mL of methylene chloride and 2 mL of trifluoroacetic acid was stirred at room temperature for 20 min. The solvent was evaporated at reduced pressure. 2-amino-3-(-(4-phosphonomethylphenyl)-N-2-{2-[benzylamino]phenyl}phenyl) propanamide was isolated as the trifluroacetic acid salt which was treated with ammonia to give 0.27 g (65%) 2amino-3-(-(4-phosphonomethylphenyl)-N-(2-{2-[benzylamino]phenyl}phenyl) propanamide. ¹HNMR (CDCl₃): δ 1.72 (2H, broad s), 2.78 (2H, s), 2.86 and 3.10 (2H, dd), 3.70 (1H, m), 4.48 (2H, s), 6.65-6.85 (8H, m), 7.00-8.50 (7H, m), 8.44 (1H, d).

EXAMPLE 36

Manganese (2,2′-diamino(bis-N,N′-quinilylmethyl)biphenyl)(Cl)₂ [FIG. 36]

To 100 mg (0.27 mmol) of 2,2′-diamino (bis-N,N′-quinilylmethyl)biphenyl in 15 mL of methanol was added a solution of 44 mg (0.27 mmol) of Mn(II)Cl₂ in 10 mL of methanol. The solution was heated for 30 min, cooled to room temperature and the solvent was evaporated to 10 mL. Crystals of Manganese (2,2′-diamino (bis-N,N′-quinilylmethyl)biphenyl)(Cl)₂ formed over 7 days which were collected and dried. Anal. Calcd for MnC₃₂C₁₂H₂₆N₄: C, 64.87; H, 4.43; N, 9.45. Found. C, 64.78; H. 4.40; N, 9.94.

EXAMPLE 37

[Iron (4chloro-2-{[(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol)(Cl)₂]Cl [FIG. 37]

To 100 mg (0.26 mmol) of 4-chloro-2-{[(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol in 15 mL of methanol was added a solution of 70 mg (0.27 mmol) of Fe(M)Cl₂ in 10 mL of methanol. The solution was heated for 30 min. cooled to room temperature and the solvent was evaporated to 10 mL. Crystals of Iron (4-chloro-2-{[(2-{2-[(2-pyridylmethylamino]phenyl}-phenyl)amino]methyl}phenol)(Cl)₂]Cl formed over 2 days which were collected and dried. Anal. Calcd for FeC₂₅C₄H₂₂N₃O: C, 51.94; H, 3.84; N, 7.26. Found, C, 52.33; H, 3.88; N, 7.41.

EXAMPLE 38

[Vanadium (2,2′-diamino(bis-N,N′-pyridylmethyl)biphenyl)Cl₂] [FIG. 38]

To 100 mg (0.27 mmol) of 2,2-diamino (bis-N,N′-pyridylmethyl)biphenyl in 15 mL of methanol was added a solution of 33 mg (0.27 mmol) of V(II)Cl₂ in 10 mL of methanol. The solution was heated for 30 min, cooled to room temperature and the solvent was evaporated to 10 mL. Crystals of [Vanadium (2,2′-diamino(bis-NN′-pyridylmethyl)biphenyl)Cl₂] formed overnight which were collected and dried (78 mg, 69%). Anal. Calcd for VC₂₄C₁₂H₂₂N₄: C, 59.00; 1,4.55; N, 11.47. Found: C, 59.43; H, 4.12; N, 11.37.

EXAMPLE 39

[Gadolinium (2,2′-diamino(bis N,N′-pyridylmethyl)biphenyl)Cl₂]Cl [FIG. 39]

To 100 mg (0.27 mmol) of 2,2′ diamino (bis-N,N-pyridylmethyl)biphenyl in 15 mL of methanol was added a solution of 100 mg (0.27 mmol) of Gd(III)Cl₃ in 20 mL of methanol. The solution was heated for 30 min, cooled to room temperature and the solvent was evaporated to 10 mL. Crystals of [Gadolinium (2,2′-diamino(bis-N,N′-pyridylmethyl)biphenyl)Cl₂]Cl formed overnight which were collected and dried (78 mg, 69%). Anal. Calcd for GdC_2-4C₁₃H₂₂N₄: C, 45.74; 11, 3.53; N, 8.89. Found: C, 45.33; H. 3.78; N, 8.82.

EXAMPLE 40

[Chromium (2-({[2(2-{[2-hydroxyphenyl)methyl]amino}phenyl)phenyl]amino}methyl)phenol)Cl)₂]Cl [FIG. 40]

To 200 mg (0.50 mmol) of 2-({[2-(2-{[2-hydroxyphenyl)methyl]anmino}phenyl) phenyl]amino}methyl)phenol in 25 mL of methanol was added a solution of 133 mg (0.50 mmol) of Cr(III)C₃ in 20 mL of methanol. The solution was heated for 30 min. cooled to room temperature and the solvent was evaporated to 20 mL. Crystals of [Chromium (2-({[2-(2-{[2-hydroxyphenyl)methyl]amino}phenyl)phenyl]amino}methyl)phenol)Cl)₂]Cl formed over 2 weeks which were collected and dried (174 mg, 63%). Anal. Calcd for CrC₂₆C₁₃H₂₄N₂O₂: C, 56.29; H, 4.37; N, 5.05. Found: C, 56.78; H, 4.42; N, 5.01.

EXAMPLE 41

Comparison of Stabilities of Metal Ion Complexes

Referring to the heats of formation, the first modification to consider is how the heats of formation are affected by changing the metal ion. The data is quite clear here with the relative stabilities following the pattern: Co>Fe>Mn>Cu>Zn>Cd. Occasionally the Cu complexes are more stable than the Mn but otherwise the trend holds consistently from one set of complexes to another. The trend in changes in stability due to changes in the metal may be exploited by recognizing the affinity that the organic compounds have for various metal ions in the body.

In Table III it is apparent that Fe 2,3,2-piperidine and Fe 2,3,2-adamantane have a low heat of formation which would be attractive to address the excess iron pools in neurodegenerative disease and the excess iron released into brain tissue following lysis of dead neurons post stroke, the adamantane having additional effect on the NMDA receptor.

Similarly from Tables II and IV it is apparent that Fe cyclam methylated and Fe cyclam adamanatane are very stable and Zn cyclam methylated and Zn cyclam adamantine not unduly stable. This behavior could be useful in treating ischemic damage post myocardial infarction where iron exerts toxic redox effects and tissue zinc stores are rapidly depleted.

From Tables II and V it is apparent that there are chain (open ring) molecules binding copper and manganese, Cu 2,3,2-isopropyl on N1/N4 and Mn 3,3,3 respectively are as stable as closed ring molecules. Thus chain (open ring) molecules are comparable with closed ring molecules in their capacity to address free metal excess in neurodegenerative diseases and stroke.

EXAMPLE 42

Ring Size

For the 2,3,2-tetramine compounds, formation of 6-membered rings when binding to metal ions increases the stability of the metal complexes. This can be seen when comparing the 3,3,3-tetramine metal complexes to the corresponding 2,3,2-tetramine and the 2,2,2-tetramine compounds. In all cases, the 3,3,3-tetramine complexes are more stable than their 2,3,2-tetramine counterparts. Also, it is generally true that the 2,3,2-tetramine complexes are more stable than the 2,2,2-tetramine complexes. This suggests that the 3,3,3-tetramine compounds may be of considerable interest as companions to the 2,3,2-tetramine compounds. Schugar R and coworkers (Inorg. Chem., 19, 940, 1980) have shown through stability constants that changing the size of the chelate ring has an effect on the resultant stability of the metal complex.

Modification of the cyclam rings so that the rings are smaller or larger also impacts the heats of formation The cyclen complexes are less stable than the cyclam rings, a result that has been documented elsewhere. Increasing the size of the ring as was done for the cyclam 3,3,3-tetramine complexes also leads to enhanced stability compared to cyclam.

These size related changes in stability influence the design of compounds for treatment of neurodegenerative disorders, stroke, glaucoma, Atherosclerosis, cardiomyopathy, ischemia, optic neuropathy, peripheral neuropathy, Presbycussis and cancer.

EXAMPLE 43

Addition of Side Groups on Chain (Open Ring) Molecules

Along with changing the size of the rings, various alkyl groups were put on the nitrogens or carbons to see how these modifications affected the stability of the complexes. A number of generalizations can be extracted from the data First, putting small alkyl groups on the nitrogens generally enhances their stability. This can be seen when comparing the 2,3,2-tetramine compounds to the ones where either N1/N4 or N2/N3 are substituted with methyl groups. This result also holds for isopropyl groups substituted on N1/N4 and generally for isopropyls on N2/N3. There is a limit to adding large groups on the nitrogens as seen by the compounds with benzyl substituents. These complexes are very much less stable than the unsubstituted 2,3,2-tetramine complexes.

The placement of alkyl groups on the carbons was only studied in a few cases, but for all of them the addition of methyls led to enhanced stability at a level comparable to that found when the methyls were placed on the nitrogens.

Addition of Side Groups on Closed Ring Molecules

The trends for the heats of formation of the cyclam complexes are not as consistent as those found for the 2,3,2-tetramine complexes. For example, putting methyl groups on the nitrogens increases the stability in some cases but decreases it in others. The same is true for the complexes where isopropyl is added to the nitrogens. Once again though, benzyl groups greatly decrease the stability of the complexes showing that there is an upper limit as to how bulky the substituents can be before the stability of the complexes is greatly diminished. Surprisingly, the addition of adamantane to the cyclams leads to enhanced stability in all cases. Adamantane is a very large group but it is able to find ways to exist so that the structure is actually quite stable. This stability of the cyclam adamantane compounds may be useful in situations such as stroke and glaucoma where NMDA receptor antagonism is required.

From a biopassaging standpoint the stability of the 2,3,2-isopropyl complexes and molecules with carbon side chains attached to the nag nitrogens or carbons is valuable toward developing compounds which are more lipophilic and thus have better passage across the gastrointestinal tract, blood brain barrier and blood retinal barrier, this being important in the treatment of Parkinson's, Alzheimer's, Lou Gehrig's, Binswanger's, Lewy Body diseases, Olivopontine Cerebellar Degeneration, Stroke, Glaucoma and Optic Neuropathy described herein.

EXAMPLE 44

Modifications of Terminal Nitrogens

Another important result is the one shown by changing N1/N4 into piperidine or piperizine nitrogens. It should be noted that these compounds are somewhat different than the ones described above in that the piperidine groups are not added to N1/N4 but rather N1/N4 are replaced by the piperidine or piperizine. With the exception of the copper complexes, these complexes are more stable than the base 2,3,2-tetramine complexes. No generalizations can be made regarding the adamantane compounds but it is noteworthy that they are not excessively unstable compared to the 2,3,2-tetramine compounds (indeed, the Fe complex is more stable while the Co one is equal in stability) even though they are quite large and bulky. This suggests that even large, bulky alkyl groups placed on the nitrogens may not adversely affect their properties and they should be pursued.

The piperidine, piperizine and adamantane derivative molecules are attractive because the terminal groups can substantially alter basicity, lipophilicity and passage through membranes, in addition to altering receptor binding properties. These derivatives may also be attractive where a selective bias towards iron removal versus stored copper removal is sought. This could be applicable to therapeutics for ischemia post myocardial infarction, atherosclerosis and neurodegenerative diseases.

Further the stability of terminally substituted derivatives provides opportunity for substitution with glutathione, uric acid, ascorbic acid, taurine, estrogen, dehydroepiandrosterone, probucol, vitamin B, hydroxytoluene, carvidilol, α-lipoic acid, α-tocopherol, ubiquinone, phylloquinone, β-carotene, meanadione, glutamate, succinate, acetyl-L-carnitine, co-enzyme Q, lazeroids, and polyphenolic flavonoids or homocysteine, menaquinone, idebenone, dantrolene.

These specific derivatives of polyamines may be used as compounds in the treatment of, though not limited to, the following diseases:

• glutathione polyamine in peripheral neuropathy and ischemia
• uric acid polyamine in stroke
• ascorbic acid polyamine in diabetic neuropathy and ischemia
• taurine polyamine in diabetic neuropathy
• estrogen polyamine in stroke
• dehydroepiandrosterone polyamine in stroke
• probucol polyamine in peripheral neuropathy
• vitamin E polyamine in peripheral neuropathy, Alzheimer's disease, stroke and ischemia,
• hydroxytoluene polyamine in peripheral neuropathy
• carvidilol polyamine in peripheral neuropathy
• α-lipoic acid polyamine in presbycussis, peripheral neuropathy and diabetic neuropathy and Alzheimer's disease
• α-tocopherol polyamine in atherosclerosis and ischemia
• menaquinone polyamine in diabetes
• ubiquinone polyamine in ischemia
• phylloquinone (Vitamin K₁) polyamine in atherosclerosis and cardiomyopathy
• β-carotene polyamine in ischemia
• glutamate polyamine in diabetes
• succinate polyamine in diabetes
• acetyl-L-carnitine polyamine in Alzheimer's disease and presbycussis
• co-enzyme Q polyamine in diabetes, cardiomyoapthy and congestive heart failure
• lazeroid (21 aminoquinone) polyamine in stroke
• polyphenolic flavonoid (quercetin, catechin, epicatechin) polyamine as antioxidants
• homocysteine polyamine in cancer
• meanadione (Vitamin K₃) polyamine in cardiomyoapthy
• idebenone polyamine in cardiomyoapthy, MELAS and stroke
• dantrolene polyamine in stroke
• Memantine polyamine, rimantadine polyamine in glaucoma

EXAMPLE 45

Internal Substitutions in the Open Chain (Ring) Molecules

It is also possible to replace the nitrogens with other donors such as sulfur. As shown, these complexes excepting the iron ones are considerably more stable than the nitrogen ones. Sulphur containing polyamines terminally derivatized with homocysteine could be used as anti-cancer agents.

Internal Substitutions in the Closed Ring Molecules

Replacing the nitrogens with sulfur enhances the stability of some complexes (Cu, Zn, Co) but not in others (Fe, Mn). This result shows that it is possible to build into the organic compounds selectivity for some metal ions over others. Again a sulphur containing closed ring polyamine derivatized with homocysteine could be used as an anti-cancer agent.

EXAMPLE 46

Pharmacokinetic Advantages Versus Stability of Derivatives

Terminal modifications and side chain additions alter pKa, lipophilicity and also the metabolism of these compounds, thus changing half life in vivo. 2,2,2-tetramine is rapidly metabolized to acetyl 2,2,2-tetramine and rapidly excreted with a half life in vivo of only a few hours (Kodama H et al 1997). This metabolism will obviously be altered considerably in terminally derivatized compounds and to some extent in molecules with side chains attached and in internally derivatized molecules. In the treatment of the diseases mentioned above a longer half life and less frent dosing such as once daily dosing will be highly advantageous for therapeutic effect and patient compliance.

Additional Comments

The results in Tables I to VIII shed light on the stability of these molecules and helps direct which ones are appropriate for particular disease situations based upon metal ion selectivity and pharmacological actions and how to enhance the bioavailability of orally or parenterally delivered drugs, and drugs crossing particular membranes such as the blood brain barrier and blood retinal barrier.

EXAMPLE 47

Oil Water Partition Coefficients

Partition coefficients were determined by dissolving the compound in a 1:1 mixture of octanol/water and shaking the solution for 12 hours. HPLC was used to determine the partition coefficient The reported values are the log of the octanol/water partition

TABLE IX

Oil Water Partition Coefficients

Log Partition Coefficient

Compound

Octanol:Water

2,2,2-tetramine

1.6

2,3,2-tetramine

2.1

2,3,2-pyridine

2.7

2,3,2-CH₃ on N1/N4

0.4

cyclam-piperidine

0.7

Octanol: water partition log partition coefficients of 2 are optimal for passage through lipid membranes and tissue barriers. Molecules within a range from 0.5 to 4.0 are potential candidates for in vivo use. Thus 2,2,2-tetramine, 2,3,2-tetramine and 2,3,2-pyridine have optimal lipid water partitioning to facilitate their passage through the gastrointestinal barrier and the blood brain barrier.

EXAMPLE 48

PKa's

PKa's were determined by standard potentiometric titration methods in aqueous solution with an ionic strength of 0.10 at 25° C. Values are reported as log K values of the equilibrium constant

TABLE X

pKa's

pKa(1)

pKa(2)

pKa(3)

pKa(4)

2,2,2-tetramine

9.7

9.1

6.6

3.3

2,3,2-tetramine

10.3

9.5

7.3

6.0

2,3,2-pyridine

8.3

7.4

2,3,2-piperidine

9.9

9.3

6.4

3.6

2,3,2-tetramethyl

10.2

9.4

6.1

2.9

tetramethylcyclam

9.7

9.3

3.1

2.6

2,3,2-pyridine is less basic and thus more soluble at neutral pH than some of the other amines.

Selection of compounds with appropriate pKa's for use in various diseases where low pKa's would be useful. Selection of compounds with appropriate pKa's for use in various diseases where higher pKas would be useful such as in diabetes and post myocardial infarction.

Experimental Method of Measuring Bacterial Survival in Examples 49-54.

Bacteria were innoculated and cultured in nutrient agar for eighteen hours, using a shaking incubator at 140 r.p.m and 35° C. Medium contained 10 mM H[PES buffer at pH 7. Cells were centrifuged twice in Sorval RC-5 centrifuge 12,000 r.pm.×15 minutes at 4° C. and washed twice in 10 uM HEPES buffer. The resuspended cells were counted using a Hemocrit and diluted to a level of 5×10¹ cells per ml in 10 μM HEPES. The cells, the following toxins; methyl viologen (paraquat), methyl viologen (MPP⁺), rotenone, daizoxide, streptozotocin and alloxan, and antidotes were added, reaching final volumes of 1 ml in Epppendorf tubes and placed on a rotator at room temperature. 10 μM diethylenetriaminepentaacetic acid was added to the samples to terminate the reactions at the specified times of either twenty or sixty minutes. 300 μL of cells were plated on Petri plates containing nutrient agar and incubated at 35° C. overnight. Colonies were counted after 20 hours. Percentage survival as compared with culture controls is calculated from the means of triplicates in each experimental group. Bacteria utilized were E. coli, S. aureus, M. luteus ATCC strains and GM 7359 alkA tag E. coli mutant (Minus ILG. et al 1988 and 1989). Histidine was used for comparison purposes because it ahd previously been reported efficacious in counteracting MPP⁺ and paraquat toxicity in E. Coli (Haskel Y. et al 1991).

EXAMPLE 49

TABLE XI

Toxins and Antidotes PARAQUAT

Organism: E. coli (ATCC 35150)

Toxin: Paraquat

Antidotes: Histidine, Spermine and 2,3,2-tetramine

Incubation Time: 60 minutes

Analysis of Variance Table

Sum

Mean

Source:

DF:

Squares:

Square:

F-test:

Between groups

11

3.546

.322

35.864

Within groups

24

.216

.009

p = .0001

Total

35

3.762

Model II estimate of between component variance = .104

Samples

Mean %

PLSD

Survival Fisher

Culture

100

0.5 mM Histidine

100

1 mM Histidine

100

0.5 mM Spermine

100

1 mM Spermine

96

1 mM 2,3,2-tetramine

100

0.5 mM Paraquat

16

1 mM Paraquat

10

0.5 mM Paraquat + 0.5 mM Histidine

30

0.217

0.5 mM Paraquat + 1.0 mM Histidine

37

0.217

0.5 mM Paraquat + 0.5 mM Spermine

60

0.217 Sig. at 99%

1.0 mM Paraquat + 0.5 mM Spermine

100

0.217 Sig. at 99%

1.0 mM Paraquat + 1.0 mM 2,3,2-tetramine

100

0.217 Sig. at 99%

Spermine and 2,3,2-tetramine were more efficacious in preventing cell loss than histidine at comparable doses.

TABLE XII

Toxins and Antidotes PARAQUAT

Organism: S. aureus (ATCC 29213)

Toxin: Paraquat

Antidotes: 2,3,2-tetramine and Cyclam

Incubation Time: 60 minutes

Analysis of Variance Table

Sum

Mean

Source:

DF:

Squares:

Square:

F-test:

Between groups

6

.884

.147

66.512

Within groups

14

.031

.002

p = .0001

Total

20

.915

Model II estimate of between component variance = .048

Samples

Mean %

PLSD

Survival Fisher

Culture

100

0.5 mM 2,3,2-tetramine

100

1 mM 2.3,2-tetramine

100

30 uM Cyclam

87

0.5 mM 2,3,2-tetramine

39

0.5 mM Paraquat

39

0.5 mM Paraquat + 0.5 mM 2,3,2-tetramine

78

0.114 Sig. at 99%

0.5 mM Paraquat + 1 mM 2,3,2-tetramine

80

0.114 Sig. at 99%

0.5 mM Paraquat + 30 uM Cyclam

71

0.114 Sig. at 99%

2,3,2-tetramine and cyclam protected against paraquat induced cell killing, paraquat being effective at lower doses than 2,3,2-tetramine.

EXAMPLE 50

TABLE XIII

Toxins and Antidotes MPP⁺

Organism: S. aureus (ATCC 29213)

Toxin: MPP⁺

Antidotes: Histidine, 2,3,2-piperidine, Cyclam and Cyclam Adamantane

Incubation Time: 60 minutes

Analysis of Variance Table

Sum

Mean

Source:

DF:

Squares:

Square:

F-test:

Between groups

19

5.847

.308

29.918

Within groups

58

.597

.01

p = .0001

Total

77

6.444

Model II estimate of between component variance = .078

Samples

Mean %

PLSD

Survival Fisher

Culture

100

0.5 mM Histidine

90

7.5 uM 2,3,2-piperidine

100

30 uM Cyclam

81

30 uM Cyclam Adamantane

100

0.1 mM MPP⁺

31

0.15 mM MPP⁺

15

0.2 mM MPP⁺

6

0.25 mM MPP⁺

3

0.15 mM MPP⁺ 0.5 mM Histidine

64

0.242 Sig. at 99.5%

0.25 mM MPP⁺ + 1 uM 2,3,2-

54

0.242 Sig. at 99.5%

piperidine

0.25 mM MPP⁺ + 2 uM 2,3,2-

54

0.242 Sig. at 99.5%

piperidine

0.25 mM MPP⁺ + 5 uM 2,3,2-

69

0.242 Sig. at 99.5%

piperidine

0.25 mM MPP⁺ + 7 uM 2,3,2-

100

0.191 Sig. at 99.5%

piperidine

0.15 mM MPP⁺ + 30 uM Cyclam

79

0.242 Sig. at 99.5%

0.2 mM MPP⁺ + 1 uM Cyclam

100

0.242 Sig. at 99.5%

Adamantane

0.2 mM MPP⁺ + 2.5 uM Cyclam

100

0.242 Sig. at 99.5%

Adamantane

0.2 mM MPP⁺ + 5.0 uM Cyclam

100

0.242 Sig. at 99.5%

Adamantane

0.2 mM MPP⁺ + 7.5 uM Cyclam

100

0.242 Sig. at 99.5%

Adamantane

Micromolar doses of 2,3,2-piperidine and cyclam adamantane protected against 200 uM doses of MPP⁺ whereas histidine was only effective in substantially higher dose.

EXAMPLE 51

TABLE XIV

Toxins and Antidotes ROTENONE

Organism: E. coli (GM 7359) alkA tag E. coli mutant

Toxin: Rotenone

Antidotes: 2,3,2-piperidine, 2,3,2-pyridine, Chromium 2,3,2-pyridine,

2,2,2-tetramine, 2,3,2-diCH₃ and Cyclam Adamantane

Incubatiion Time: 60 minutes

Analysis of Variance Table

Sum

Mean

Source:

DF:

Squares:

Square:

F-test:

Between groups

31

.911

.029

5.955

Within groups

103

.508

.005

p = .0001

Total

134

1.419

Model II estimate of between component variance = .006

Samples

Mean %

PLSD

Survival Fisher

Culture

100

50 uM 2,3,2-piperidine

100

50 uM 2,3,2-pyridine

100

1 uM Chromium 2,3,2-pyridine

100

2 mM 2,2,2-tetramine

100

25 uM 2,3,2-diCH3

100

25 uM Cyclam Adamantane

100

100 uM Rotenone

60

100 uM Rotenone + 2.5 uM 2,3,2-piperidine

100

0.182 Sig.

at 99.8%

100 uM Rotenone + 5 uM 2,3,2-piperidine

100

0.182 Sig.

at 99.8%

100 uM Rotenone + 20 uM 2,3,2-piperidine

100

0.182 Sig.

at 99.8%

100 uM Rotenone + 50 uM 2,3,2-piperidine

100

0.182 Sig.

at 99.8%

100 uM Rotenone + 2.5 uM 2,3,2-pyridyine

100

0.182 Sig.

at 99.8%

100 uM Rotenone + 5 uM 2,3,2-pyridyine

100

0.182 Sig.

at 99.8%

100 uM Rotenone + 20 uM 2,3,2-pyridyine

100

0.182 Sig.

at 99.8%

100 uM Rotenone + 50 uM 2,3,2-pyridyine

100

0.182 Sig.

at 99.8%

100 uM Rotenone + 1 um Chromium 2,3,2-pyridine

100

0.182 Sig.

at 99.8%

100 mM Rotenone + 0.5 mM 2,2,2-tetramine

67

0.182

100 mM Rotenone + 2 mM 2,2,2-tetramine

100

0.182 Sig.

at 99.8%

100 uM Rotenone + 2.5 uM 2,3,2-diCH₃

100

0.182 Sig.

at 99.8%

100 uM Rotenone + 5 uM 2,3,2-diCH₃

89

0.182 Sig.

at 99.8%

100 uM Rotenone + 12.5 uM 2,3,2-diCH₃

100

0.182 Sig.

at 99.8%

100 uM Rotenone + 25 uM 2,3,2-diCH₃

100

0.182 Sig.

at 99.8%

100 uM Rotenone + 2.5 uM Cyclam Adamantane

97

0.182 Sig.

at 99.8%

100 uM Rotenone + 5 uM Cyclam Adamantane

89

0.182 Sig.

at 99.8%

100 uM Rotenone + 12.5 uM Cyclam Adamantane

100

0.182 Sig.

at 99.8%

100 uM Rotenone + 25 uM Cyclam Adamantanane

100

0.182 Sig.

at 99.8%

Low micromolar doses of 2,3,2-pyridine, 2,3,2-diCH₃ and cyclam adamantane protected against rotenone induced cell killing.

EXAMPLE 52

TABLE XV

Toxins and Antidotes DIAZOXIDE

Organism S. aureus (ATCC 29213)

Toxin: Diazoxide

Antidotes: Histidine, Spermine, 2,3,2-tetramine, 2,3,2-piperidine,

2,3,2-pyridine and Cyclam

Incubation Time: 60 minutes

Analysis of Variance Table

Sum

Mean

Source:

DF:

Squares:

Square:

F-test:

Between groups

25

2.688

.108

5.668

Within groups

76

1.442

.019

p = .0001

Total

101

4.13

Model II estimate of between component variance = .023

Samples

Mean %

PLSD

Survival Fisher

Culture

100

0.5 mM Histidine

100

5 uM Spermine

99

20 uM 2,3,2-tetramine

99

10 uM 2,3,2-piperidine

100

5 uM 2,3,2-pyridine

99

10 uM Cyclam

100

0.15 mM Diazoxide

25

0.15 mM Diazoxide + 500 uM Histidine

58

0.36

0.15 mM Diazoxide + 5 uM Spermine

71

0.36 Sig.

at 99.8%

0.15 mM Diazoxide + 2.5 uM 2,3,2-tetramine

65

0.36 Sig.

at 99.8%

0.15 mM Diazoxide + 5 uM 2,3,2-tetramine

78

0.36 Sig.

at 99.8%

0.15 MM Diazoxide + 10 uM 2,3,2-tetramine

78

0.36 Sig.

at 99.8%

0.15 mM Diazoxide + 20 uM 2,3,2-tetramine

75

0.36 Sig.

at 99.8%

0.15 mM Diazoxide + 2.5 ,2,3,2-piperidine

100

0.36 Sig.

at 99.8%

0.15 mM Diazoxide + 5 uM 2,3,2-piperidine

91

0.36 Sig.

at 99.8%

0.15 mM Diazoxide + 10 uM 2,3,2-piperidine

92

0.36 Sig.

at 99.8%

0.15 mM Diazoxide + 2.5 uM 2,3,2-pyridine

61

0.36 Sig.

at 99.8%

0.15 mM Diazoxide + 5 uM 2,3,2-pyridine

84

0.36 Sig.